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between fully functional HSCs and progenitors, and LNK deficiency tips the balance towards HSCs. This is a
cell-intrinsic process, and may be regulated by gene expression-dependent and –independent functions of
LNK.
Taken together, the data presented in this thesis describes a novel role for cytokine signaling in HSC genome
stability, and deepens our understanding of how LNK influences self-renewal and genome stability. Hopefully,
these findings can contribute to the foundation of work that may result in the development of novel
therapeutic approaches to treat bone marrow failure and genome instability in HSCs.
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ABSTRACT 
 
THE ROLE OF LNK ADAPTOR PROTEIN IN HEMATOPOIETIC STEM CELL GENOME 
STABILITY AND SELF-RENEWAL 
Joanna Balcerek 
Wei Tong 
 
Hematopoietic	stem	cells	(HSCs)	are	rare	cells	that	reside	in	bone	marrow.	HSCs	function	to	give	
rise	to	all	blood	cells	through	proliferation	and	differentiation,	but	also	to	HSCs	in	a	tightly	
regulated	process	known	as	self-renewal.	It	is	for	these	abilities	that	stem	cells	stand	out	from	
progenitors	and	other	short-lived	cells	and	which	allows	them	to	last	a	lifetime.	Self-renewal	
remains	mechanistically	enigmatic	but	central	to	the	biology	and	long	lifespan	of	HSCs.	Because	
HSCs	are	so	long-lived	they	face	numerous	genomic	insults	and	therefore	mechanisms	of	
genome	stability	are	also	central	to	HSC	function	throughout	life.	
	
This	thesis	examines	the	role	of	an	adaptor	protein	known	as	LNK	(SH2B3),	which	negatively	
regulates	a	central	cytokine	signaling	axis	in	HSCs,	in	regulating	HSC	self-renewal	and	genome	
stability.	HSCs	in	Lnk-/-	mice	are	expanded,	and	endowed	with	enhanced	proliferative	and	self-
renewal	capabilities.	Given	this	superiority,	this	thesis	first	investigates	the	impact	of	LNK	
deficiency	in	context	of	a	bone	marrow	failure	syndrome,	Fanconi	Anemia	(FA),	where	HSCs	
accumulate	fatal	levels	of	genomic	insults	and	cannot	function.	Superimposed	on	the	deletion	of	
a	central	gene	in	FA,	FANCD2,	Lnk	deficiency	rescues	HSC	function	through	restoring	genome	
stability	at	sites	of	stress	encountered	during	DNA	duplication.	
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Second,	using	a	model	that	is	capable	of	tracking	HSC	divisions	in	vivo,	this	thesis	investigates	
the	in	vivo	self-renewal	dynamics	of	Lnk	deficient	HSCs.	On	a	population	level,	HSCs	exist	along	a	
continuum	of	states	between	fully	functional	HSCs	and	progenitors,	and	LNK	deficiency	tips	the	
balance	towards	HSCs.	This	is	a	cell-intrinsic	process,	and	may	be	regulated	by	gene	expression-
dependent	and	–independent	functions	of	LNK.	
	
Taken	together,	the	data	presented	in	this	thesis	describes	a	novel	role	for	cytokine	signaling	in	
HSC	genome	stability,	and	deepens	our	understanding	of	how	LNK	influences	self-renewal	and	
genome	stability.	Hopefully,	these	findings	can	contribute	to	the	foundation	of	work	that	may	
result	in	the	development	of	novel	therapeutic	approaches	to	treat	bone	marrow	failure	and	
genome	instability	in	HSCs.	
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CHAPTER 1  
Introduction 
	
The hematopoietic system is a highly proliferative organ, producing and replacing billions 
of hematopoietic cells every day. This is sustained through production of hematopoietic 
cells from a population of hematopoietic stem cells (HSCs). These are rare cells with the 
two defining properties: 1) being able to repopulate an entire hematopoietic system 
(multi-lineage repopulation capacity), and 2) being able to produce additional HSCs 
(self-renewal) (Fig 1.1). HSCs are long-lived and therefore how HSCs handle genotoxic 
insults is especially important to their longevity and health. This thesis focuses on 
understanding the role of cytokine signaling in genome protection through a model of 
augmented cytokine signaling. 
 
1.1 Hematopoietic stem cells 
1.1.1 Functional Identification of HSCs 
 
In order to study HSCs, it is essential to identify them. This has not been a trivial 
undertaking. HSCs reside primarily in the bone marrow, in specialized niches near slow-
flowing blood vessels with low oxygenation 1. HSCs were first described functionally, 
through the successful reconstitution of a recipient by transplant of donor bone marrow 
(BMT) 2 3 4. This revelation led to a field of study dedicated to unraveling the inner 
workings of HSCs and their roles in normal and malignant hematopoiesis.  
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The gold standard for functional identification of HSCs remains the BMT where an HSC 
is defined as a single cell capable of reconstituting a conditioned recipient indefinitely 5. 
To test for the total number of functional HSCs, total bone marrow is harvested from 
donors and injected into lethally irradiated recipients. HSC function is measured in the 
peripheral blood monthly for four months. Generally, HSC activity is scored if there is 
reconstitution above 1% across all lineages for the entire four month period 6 7 8 9. An 
expected ratio of lymphoid to myeloid production is produced based on whether the HSC 
is lineage-biased or balanced 10.  Several doses are tested and by this method, it is 
possible to quantitate the number of functional HSCs in bone marrow. Similarly, 
reconstitution by BMT is used to test whether HSCs are present in a specific population 
of interest.  
 
Transplantation is also used to directly test the second key aspect of HSC identity: self-
renewal. At the end of the first BMT, phenotypic HSC – assessed by surface marker 
profiles that have been correlated with functional HSCs – are enumerated in the BM. 
This provides a first-approximation estimate of the extent to which HSCs self-renewed 
over the course of the transplant. However, self-renewal is rigorously assessed by 
secondary transplant of BM from the recipients of the primary BMT 11 12 13 14.  
 
Self-renewal ensures a continued HSC pool throughout the lifespan of the organism. 
HSC self-renewal has been described at the moment of cell division as an inheritance of 
HSC fate in one or both daughter cells through asymmetric or symmetric division, 
respectively 15 16. However, HSCs are found to undergo division rarely, existing in a state 
	3	
	
of quiescence 17 18 19. During hematopoietic depletion or immune challenge, HSCs 
respond to the stress by proliferating and differentiating to produce hematopoietic 
effector cells and then return to quiescence 20,21. However, the proliferative capacity of 
HSCs is also limited and prolonged stress results in bone marrow failure 22-24. Together 
self-renewal and reconstitution capacity constitute the definition of functional HSCs. 
 
1.1.2 Phenotypic Identification of HSCs 
To study HSCs, it is necessary to prospectively identify and isolate them from the 
progenitors and stromal cells that also reside in the bone marrow. One way to do so has 
been based on determining the surface marker expression profile of cells with 
reconstitution capacity by flow cytometry. Mature lineage-specific cells are excluded by a 
combination of empirically-determined surface markers associated with each of the 
lineages and includes Ter-119 (red blood cells), Gr-1, Mac-1 (myeloid), CD3, CD4, 
CD8a (lymphoid), and CD19 and B221 B cells), which are collectively termed Lin 
markers. The remaining cells are enriched for HSC and progenitors 25,26 . This population 
is further enriched for HSCs by selecting for cells expressing c-kit and Sca-1 27,28 29 25. 
Further separation between short-term repopulating cells and long-term repopulating 
HSCs (LT-HSCs) has been achieved by addition of other surface markers: CD48-
CD150+ (SLAM LSK) 11,30 or CD34-Flk2- 5,31, ESAM 32,33, side-population 34 or most 
recently Sca1hiEPCRhi LSK 35. These surface marker schemes are capable of enriching 
HSCs to 1 in every 3 cells, or 1 in 2 cells, respectively.  
 
	4	
	
Though these surface markers do enrich HSCs, there are several important caveats 
about phenotypic HSC markers. The first is that any given surface marker of an HSC 
may or may not contribute to HSC function. For example, c-kit or Sca-1 ablation 
negatively impacts HSC function 28,29. Second, because not all surface markers are 
coupled to HSC function, there is not a perfect correlation between surface markers and 
functional HSCs. For example, some cells marked by CD150+ within CD48-LSK, are not 
functional HSCs, while some CD150- are 36. In this way, there are several distinct and 
partially overlapping surface marker schemes that enrich HSCs, and none can 
encompass all HSCs. Finally, the expression level of surface markers also correlates 
with function. High cell surface expression of either Sca1 or CD150 is associated with 
functional HSCs 35,37, while high expression of c-kit is associated with short-term HSCs 
38,39. Together these caveats contribute to the difficulty of phenotypic isolation of HSCs. 
 
1.2 Cytokine signaling in HSCs 
	
	
1.2.1 Cytokines involved in HSC self-renewal 
	
HSCs are regulated through multiple cell- autonomous and –nonautonomous 
mechanisms. One crucial cell-autonomous mechanism is through cytokines. Cytokines 
are short hydrophilic peptides that are recognized by cognate receptors on the cell 
surface and trigger a series of signaling events inside the cell. In general, cytokines 
trigger HSC and progenitor survival, proliferation, differentiation, and lineage 
commitment. Two cytokines have been shown to be essential to the maintenance of 
HSCs: stem cell factor (SCF) and Thrombopoietin (TPO) 27-29,40-42. 
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This thesis focuses on the contribution of TPO signaling to HSC maintenance. TPO 
binds and signals through its cognate receptor (TPOR). TPOR lacks intrinsic kinase 
activity, and is associated with the tyrosine kinase JAK2. TPO/TPOR/JAK2 signaling is 
essential to HSC survival, proliferation, and self-renewal 43 44. Mice deficient for TPO or 
TPOR have a contracted HSC compartment, and these HSCs are severely functionally 
impaired in transplant assays 41,45-47 48. Furthermore, JAK2 deficiency is embryonic lethal 
49 50. Therefore TPO/TPOR/JAK2 is an important pathway in the study of HSC self-
renewal. 
 
1.3 Role of Lnk deficiency in HSCs 
	
LNK is the third member in the SH2 domain containing family of adaptor proteins. This 
family of proteins function in a variety of cell contexts to curb cytokine signaling 
specifically in glucose metabolism and immune cell activation {Devalliere:2011fl} 51,52. 
LNK is the main member of this family to be expressed in HSCs. In HSCs, one of the 
main targets of LNK is JAK2. LNK directly binds to and inhibits the activity of JAK2, and 
therefore negatively regulates TPO/TPOR/JAK2 signaling 53. Consequently LNK 
deficiency increases TPO mediated cytokine signaling in cells (Fig 1.2). 
 
1.3.1 Lnk deficient HSCs 
	
In Lnk deficient animals, Lnk deficiency results in a progressive HSC expansion, such 
that the HSC compartment is 10-fold expanded in young adult animals. Furthermore, 
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Lnk deficient HSCs provide enhanced reconstitution in recipients 54-56. Importantly, Lnk-/- 
HSCs show enhanced self-renewal in vivo and in vitro 8,56. However, in contrast to the 
deleterious consequences observed in mice with activating mutations in components of 
TPO/TPOR/JAK2 signaling such as JAK2 V617F 57 58 59 or constitutive AKT activity 60, 
Lnk deficiency does not lead to premature depletion of HSCs 61 nor to uncontrolled 
proliferation and neoplasm. In fact, the expanded HSC compartment in Lnk-/- mice is 
mostly quiescent 56 (Fig 1.3).  Taken together, Lnk deficient HSCs show many 
enhancements in HSC function, rendering Lnk as a potentially valuable therapeutic 
target in the expansion and transplantation of HSCs.  
 
Though the immediate signaling consequences of Lnk deficiency on TPO signaling have 
been described, much of the downstream consequences of the augmentation in TPO 
signaling on HSC biology remain elusive.  
 
1.4 Fanconi Anemia 
	
1.4.1 Fanconi Anemia clinical manifestations 
	
Fanconi Anemia (FA) is a hereditary set of disorders that affect genome stability in cells, 
first described over 85 years ago 62. Though there is a spectrum of physical 
deformations and extent to which FA may affect an individual, a feature that is nearly 
ubiquitous among FA patients is bone marrow failure (BMF) 63. FA is the most commonly 
inherited BMF syndrome, and is universally associated with a shortened life span 64. FA 
is caused by a bi-allelic mutation in one of 21 Fanconi genes that cooperate to maintain 
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genome integrity and repair and include tumor suppressors Brca1 and Brca2 64,65. To 
date there is no cure for FA. 
 
However, the BMF in FA is now treatable. Until recently, there was no treatment for BMF 
in FA patients because of the risk of inducing cancerous mutations in other tissues by 
chemotherapeutics that would clear space for donor bone marrow. Recent advances in 
recipient conditioning through gentler agents has enabled bone marrow transplant 
(BMT), which allows for lifespan extension in FA patients 66-68. Nevertheless, FA patients 
are at a higher risk for developing leukemia and epithelial cancers 69-71. 
 
1.4.2 FA proteins; FANCD2 
	
FA family proteins function in a variety of roles. The best-known role of FA proteins is in 
context of DNA crosslink repair, in which a damaging agent covalently crosslinks two 
DNA strands 72,73. This is known as an interstrand crosslink (ICL). Upon replication, this 
crosslink halts DNA replication and is then recognized by the core complex, which 
ubiquitinates and activates FANCD2 (D2) in the FANCD2-FANCI (I-D2) recognition 
complex 74. The activated I-D2 complex then recruits downstream effectors that process 
the crosslink to a double stranded break (Fig 1.4A). This in turn activates strand repair 
machinery to repair the DSB through homologous recombination and ultimately, the 
resumption of replication 75. In the absence of a FA protein, this network falls apart and 
repair is diverted to error-prone processes such as non-homologous end joining, while 
genome instability is concurrently dramatically elevated 76 77. 
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If crosslinks are not resolved they are lethal to cells. Unsurprisingly, FA cells have a high 
level of genome instability and a hallmark aberrant chromosomal profile in metaphase 
spreads 64 78, a higher rate of spontaneous apoptosis in culture, and are extremely 
sensitive to crosslinking agents, such as Mitomycin (MMC) 78 72. Collectively, these 
defects result in apoptosis, shrinking of the HSC pool and ultimately BMF.  
 
1.4.3 FANCD2 role in maintaining replication fork stability 
	
In addition to the ICL repair complex, FANCD2 is a central component of a second FA 
complex, which is less extensively characterized. In this role, FANCD2 is recruited to 
stalled replication forks – due to any cause 79  – and is indispensible in maintaining the 
integrity of the stalled replication fork, preventing new origin firing during stalling, and 
ultimately, in restarting stalled forks 80 79. Among binding other effectors, FANCD2 binds 
RAD51, a DNA binding protein essential for replication fork stability 81-84 (Fig 1.4B). 
Though it is unclear how FANCD2 and RAD51 interact, RAD51 overexpression is 
sufficient to overcome the fork replication associated defects in FancD2 deficient cells 80, 
underscoring both the essential role of RAD51 and the importance of further dissection 
into the regulation of this interaction. 
 
In FANCD2 deficient cells, upon stalling, replication forks are extensively resected by the 
nuclease MRE11 85, which also plays a role in normal fork restarting 86 87. This 
progresses to a double stranded break, which then must be repaired by an error prone 
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mechanism. Though not the most commonly mutated gene in FA, mutations in FANCD2 
are associated with the most severe FA and the earliest onset BMF in patients. 
Moreover, Fancd2 deficient cells have more genome instability in mice than FANCC or 
FANCG deletion 88.  Additionally, there is never complete absence of FANCD2 protein in 
patient cells 75, underscoring the importance of FANCD2 to cell survival. Additionally, in 
context of BRCA1 or BRCA2 deficiency, FANCD2 deletion dramatically increases 
genome instability 89,90. Undoubtedly, FANCD2 is central to genome stability and HSC 
survival. 
 
1.4.4 Mouse models of FA 
	
FA has been modeled in mice and there exists a few germline deleted lines of FA genes: 
Fanca 91, Fancc 92 93 94, Fancg 95 and FancD2 96-98. These mouse models recapitulate the 
cellular hallmarks associated with FA: sensitivity to MMC, high spontaneous rate of 
apoptosis, and genomic instability. Additionally, in FancD2-/- mice the HSC and 
progenitor compartment – LSK – is two-fold contracted relative to normal mice, and 
there is evidence of accelerated neoplasia 99,100. 
 
However, the hematological manifestations of FA are not observed in mice. FA mice do 
not develop spontaneous BMF, and rarely spontaneous leukemia. It is speculated that 
given the short lifespan of mice, their clean housing conditions and limited exposure to 
hematopoietic stressors such as infection, there is simply no opportunity to develop BMF 
spontaneously 63.  
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Which functions of FA proteins contribute to maintenance of BM is still an active area of 
investigation (Fig 1.5). For FANCD2, studies have revealed an important relationship: 
both roles of FANCD2 are known to contribute towards preventing BMF. Several studies 
have shown that the role of FANCD2 in crosslink repair is essential: FancD2-/- mice in 
combination with deletion of Aldehyde dehydrogenase 2 or Alcohol dehydrogenase 5 
(Aldh2, Adh5, respectively) do spontaneously develop BMF or leukemia 101 102 103 104. 
Equally importantly, prolonged stress hematopoiesis also induces BMF in FancD2-/- 
mice 105 106, especially chronic proliferation induced by the pro-inflammatory double 
stranded DNA mimic polyiosinic:polycytidylic acid (pI:pC) 105. Here, in contrast to 
crosslink- induced damage, BMF occurs as a result of proliferation-induced RNA 
damage in LT-HSCs, which are repeatedly forced into cell cycle by the injections and 
accrue damage over time.  
 
In this study, we have chosen to use FancD2-/- mice as a model for FA diseases 
because of its centrality to FA roles with demonstrated roles in maintaining HSC 
integrity.  
 
1.5 Scope and findings of this thesis 
	
The main purpose of this thesis is to explore how LNK deficiency confers enhanced 
stem cell properties to HSCs. This functionality is explored in two ways: first, by its role 
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in ameliorating hematopoietic defects in FANCD2 deficient mice, and second in its role 
in regulating self-renewal in HSCs. 
 
1.5.1 To define mechanism by which LNK deficiency rescues HSPC function in FA 
 
There have been a few reports suggesting that control over inflammatory signaling via 
TGFb attenuation 107 can ameliorate FA in mice. Notwithstanding, there are no curative 
interventions for FA. However, given the sufficiency of RAD51 overexpression in 
correcting FancD2-/- cells 80, it is clear that FANCD2 deficiency can be overcome 
molecularly.  
 
This thesis presents compelling evidence that Lnk deficiency ameliorates HSC function 
in FancD2-/- mice. Lnk deficiency does not impact crosslink repair in FancD2-/- cells, but 
does completely rescue instability in stalled replication forks. This process is JAK2 and 
TPOR –dependent, demonstrating for the first time a direct role for cytokine signaling in 
genome stability. 
 
1.5.2 To deepen the understanding by which Lnk deficiency modulates HSC self-
renewal 
	
Second, this thesis presents a model in which to study the enhanced HSC self-renewal 
conferred by LNK deficiency in vivo using the H2B-GFP mouse model. Phenotypic HSCs 
show stratification in HSC function based on division history in vivo, and therefore this 
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model provides a functional way to prospectively examine HSC function. Our in vivo and 
in vitro data show that a gradual cell-intrinsic change in HSCs takes place with each in 
vivo division.  Our genome wide expression profiling further corroborates these findings 
and offers insight into potential pathways that may be affected by LNK deficiency.   
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1.8 Figure Legends 
	
	
 
Figure 1.1: HSCs give rise to all hematopoietic cells and self-renew. HSCs sit atop the 
hematopoietic hierarchy, producing all hematopoietic cells. Arrows indicate cell identity 
transitions, which are not exhaustively drawn. Curved arrow indicates self-renewal. 
 
 
Figure 1.2: TPO signaling is enhanced in absence of LNK. (A) shows a model of TPO 
signaling in HSCs, and the inhibitory effect of LNK. Signal transduction is depicted by arrows. 
Phosphorylations are represented as red circles. (B) shows augmented signaling in Lnk deficient 
cells, as indicated by thickened arrows. Thickness is not directly proportional to signal 
augmentation.  
 
Figure 1.3: Several HSC properties are enhanced in Lnk deficient mice. 
 
Figure 1.4: FA proteins play two distinct roles in protecting genome stability. (A) shows the 
FA proteins involved in ICL repair. FA proteins are noted by the single-letter code of their 
complementation groups. (B) shows the FA proteins involved in stalled replication fork repair. The 
hovering traffic light indicates stalled replication fork conditions. 
 
Figure 1.5: Relative importance of the two roles of FA complex in HSC survival.
	27	
	
CHAPTER 2 
Lnk/Sh2b3 Deficiency restores Hematopoietic Stem Cell function and genome integrity 
in Fanconi Anemia mutant mice 
 
Joanna Balcerek 1,2,4, Jing Jiang1,2,4 , Qinqin Jiang 3, Krasimira Rozenova 1,2, Weihau Li 3, 
Roger A. Greenberg 3, and Wei Tong 1,2, * 
1 Division of Hematology, Children's Hospital of Philadelphia, 
Philadelphia, PA 19104  
2 Department of Pediatrics, Perelman School of Medicine at the University of 
Pennsylvania, Philadelphia, PA 19004 
3 Department of Cancer Biology, Abramson Cancer Research Institute and Basser 
Center for BRCA, and Perelman School of Medicine at the University of 
Pennsylvania, Philadelphia, PA 19104 
4 Equal contribution. 
 
* Correspondence and lead author: tongw@email.chop.edu 
	28	
	
2.1 Abstract 
	
Fanconi Anemia (FA) is an inherited bone marrow failure syndrome that arises due to 
mutations in a network of FA genes. FA proteins cooperate in a genome stability 
pathway that is essential for repair of DNA interstrand crosslinks (ICL) and tolerance of 
replication stress. Mutations in FA genes severely compromise hematopoietic stem cell 
(HSC) capacity, culminating in bone marrow failure and cancer predisposition. 
Importantly, interventions to mitigate HSC defects in FA do not exist, aside from 
allogeneic stem cell transplantation. Remarkably, we show here that loss of the negative 
regulator of JAK2 kinase, Lnk (Sh2b3), restores HSC function in Fancd2 knockout mice 
without further accelerating neoplastic transformation.  Lnk deficiency did not directly 
impact ICL repair but instead ameliorated replication stress by stabilizing replication 
forks in a manner dependent on cytokine-mediated JAK2 signaling. Lnk deficiency 
restored cell proliferation and survival of Fancd2-deficient HSCs to wildtype levels, while 
reducing replication stress and genomic instability associated with FA. These findings 
reveal coordination between extracellular/cytoplamic signals and processes that 
converge on replication associated genome maintenance. They also illuminate the 
diversity of mechanisms underlying the origin of bone marrow failure in FA patients and 
have implications for therapeutic strategies to treat FA associated bone marrow failure. 
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2.2 Introduction 
 
Hematopoietic stem cells (HSCs) are characterized by their ability to self-renew and 
differentiate into multilineage blood cells1,2. They are the source of all circulating blood 
cells throughout life, and disruption of HSC homeostasis is associated with a variety of 
human disorders1,2. Faithful maintenance of genome integrity in hematopoietic stem and 
progenitor cell (HSPC) populations is crucial to hematopoiesis and suppression of blood-
derived cancers. In humans, DNA repair deficiency, prominently illustrated by Fanconi 
Anemia (FA) syndromes, results in multiple congenital anomalies, progressive bone 
marrow failure (BMF) and cancer susceptibility3,4.  Mutations within nineteen genes have 
been identified as causative for FA. These genes cooperate in a genome stability 
network that is essential for repair of DNA interstrand crosslinks (ICLs) and relief of 
replication stress5. Cells derived from FA patients are hypersensitive to ICL-inducing 
agents such as Mitomycin C (MMC) and cisplatin, and exhibit DNA damage checkpoint 
and mitosis defects5. Unrepaired DNA damage in FA HSPCs increases genome 
instability and leukemia/cancer. The loss of HSPCs in FA is a consequence of multiple 
mechanisms, including impaired HSPC function, genotoxicity from the endogenous ICL 
agent, aldehydes6,7, physiological proliferative stress8, elevated p53 levels9, 
hypersensitivity to inflammatory cytokines10,11, oxidative stress12, and a hyperactive 
TGFbeta pathway13. However, how the FA pathway controls HSPC function remains 
enigmatic. Importantly, other than allogeneic transplantation, therapeutic interventions 
that mitigate the HSPC defects in FA do not exist.  
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The FA pathway involves monoubiquitination of FANCD2-FANCI proteins by the FA core 
complex in addition to a parallel or downstream function of homologous recombination 
(HR) proteins, including the breast cancer suppressor BRCA2 and BRCA114. In addition 
to their established roles in DNA repair of ICL-damage, the FA/BRCA protein network is 
also highly activated by replication stalling from depletion of nucleotide pools, such as 
from hydroxyurea (HU).  Work by Dr. Maria Jasin has uncovered a DNA repair-
independent requirement for FA proteins, including FANCD2 and BRCA1,2 in protecting 
stalled replication forks from degradation15,16.  These additional functions of the 
FA/BRCA proteins also play a critical role in preventing genomic instability and 
suppressing tumorigenesis 17. However, it remains to be determined if their roles in 
protecting stalled replication fork contribute to HSC attrition or BMF in FA.  
 
HSPC homeostasis is under the control of cytokine signaling pathways. One such 
important signaling axis is initiated by thrombopoietin (TPO) and its receptor, MPL that 
activates the JAK2 tyrosine kinase signaling pathway18. Tpo-/- and Mpl-/- mice exhibit 
marked reduction in HSC activity in supporting HSC self-renewal19,20. Patients with 
congenital amegakaryocytic thrombocytopenia (CAMT), many of whom have MPL loss-
of-function mutations, progress into BMF in childhood 21, indicating the crucial role of the 
TPO/MPL pathway in HSC homeostasis in humans.  
 
A critical negative regulator of the TPO/MPL pathway in HSCs is the adaptor protein 
LNK (or SH2B3)22-24. Lnk deficiency leads to a >10-fold increase in HSC numbers owing 
to superior HSC self-renewal23,25. Furthermore, Lnk deficiency strongly mitigates HSC 
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aging and delays HSC exhaustion in serial transplants26. We reported that LNK directly 
interacts with phosphorylated JAK2 in a TPO-dependent manner, and Lnk deficiency 
potentiates JAK2 activation and signaling in HSPCs22.  
 
In this work, we set out to test if Lnk deficiency ameliorates HSC defects associated with 
FA by generating mice double nullizygous to Fancd2 and Lnk. Remarkably, we found 
that loss of the adaptor protein Lnk restores HSC function in Fancd2-/- mice without 
accelerating neoplastic transformation. Our results indicated that LNK does not play an 
overt role in ICL repair. Instead, Lnk deficiency notably reduces spontaneous DNA 
damage and genome instability. Strikingly, we demonstrated that Lnk deficiency 
mitigates replication stress by stabilizing stalled replication forks, and that this effect is 
dependent upon cytokine-mediated JAK2 signaling. Hence, our studies shed light on the 
underlying origin of BMF in FA patients and have implications for new therapeutic 
strategies.  
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2.3 Methods and Materials 
Mice 
Fancd2-/- mice were generous provided by Dr. Alan D’Andrea (Dana Farber Cancer 
Institute) 27 and Lnk-/- mice by Dr. Tony Pawson 28 (Samuel Lunenfeld Research Institute, 
Canada), respectively. All mice were on C57/B6J background (CD45.2). Transplant 
competitor cells were from SJL (CD45.1) mice and transplant recipients were progeny of 
SJL x C57/B6J (F1). Both sexes mice of age 2-6 months old were used in the studies. 
The protocol (#2016-7-781) for this work is approved by Institutional Animal Care and 
Use committee (IACUC) of Children’s Hospital of Philadelphia (CHOP).  
 
Genotyping 
Mice were genotyped by PCR of genomic DNA from tail snips of weanling mice. Tails 
were digested at 55°C overnight in buffer containing 100mM Tris pH 8.0, 5mM EDTA pH 
8.0, 0.2% SDS and 200mM NaCl. DNA was precipitated in propanol and washed in 70% 
EtOH and then resuspended in water. Mice were genotyped for Lnk (wild-type: 5’-
gtccgactctctggctatgtggta-3’, neo insertion: 5’- cgcatcgccttctatcgcct-3’, common: 5’- 
gaagaggagtccatgtcatagtcc-3’) or FancD2 (FancD2 2F: 5’-catgcatataggaacccgaagg-3’, 
FancD2 2R: 5’caggacctttggagaagcag-3’, V76F: 5’-cttgcaaaatggcgttacttaagc-3’). 
 
Antibodies  
Antibodies used for HSC FACS and sorting were: Lineage (biotin-conjugated anti-Gr-1 
(RB6-8C5), -Mac1 (M1/70), -B220 (RA3-6B2), -CD19 (eBio1D3), -Ter110 (TER-119), -
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CD5 (53-7.3), -CD4 (GK1.5), -CD8 (53-6.7)), -c-kit (2B8), -Sca1 (E13-161.7 or D7) -
CD48 (HM48-1), -CD150 (TC15-12F12.2), -CD34 (RAM34) and –Flk2 (A2F10.1). 
Peripheral blood was analyzed using anti-CD45.1 (A20), -CD45.2 (104), -CD19 
(eBio1D3), -CD3e (145-2C11), -Gr-1 (RB6-8C5), and –Mac1 (M1/70). Cell cycle was 
assessed by Ki67 (SolA15). FACS antibodies were purchased from eBioscience, BD 
Biosciences or BioLegend. BrdU analog CldU was detected by anti-BrdU (Abcam 
BU1/75) and AF488 goat anti rat (Life Tech), and IdU by anti-BrdU (BD B44) and AF568 
goat anti mouse (Life Tech). Full antibody information is listed in Supplementary Table 1. 
 
Flow Cytometry and Cell Sorting 
For peripheral blood analysis, 50µL of peripheral blood was collected by retro-orbital 
bleed in heparinized microcapillary tubes (Drummond 1-000-7500-HC/5). Red blood 
cells were lysed with ACK lysis buffer (0.8% ammonium Chloride, 10 µM EDTA, pH 7.5 
with sodium bicarbonate). Cells were stained for donor reconstitution (CD45.1, CD45.2) 
in myeloid (Gr-1, Mac1) or lymphoid (CD19, CD3) lineages. All peripheral blood data 
was acquired using BD Canto flow cytometer and FACS DiVa software. At least 20k live 
events were recorded for each sample. APC-Cy7-conjugated anti-CD45.1, Lineage 
(biotin-Ter-119, -Mac-1, -Gr-1, -CD4, -CD8α, -CD5, -CD19 and -B220), and the HSPC 
panel: -c-kit-APC, -Sca1-PE, -CD150-PE-Cy7, -CD48-FITC, followed by staining with 
streptavidin-PE-TexasRed.  Data for bone marrow analysis was collected on the BD 
Fortessa flow cytometer and FACS DiVa software. For HSPC subset analysis, CD45.1 
was omitted and anti- CD34, and –Flk2 antibodies were added to the FACS panel. All 
flow cytometry data was analyzed using FlowJo v8.7 for MAC. 
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For sorting, HSPCs were pre-enriched using a lineage depletion kit (Miltenyi, 130-090-
858) and magnetic separation column (Miltenyi, 130-042-401) following manufacturer’s 
instructions. Briefly, bone marrow from individual mice was resuspended in 150µL of 
2mM EDTA 0.5% BSA PBS pH 7.2 (depletion buffer) and 40µL of Lineage antibody 
cocktail. Cell were incubated at 4°C for 15 minutes, then washed in 10 mL of the 
depletion buffer. Cells were resuspended in 250µL depletion buffer and 70µL Biotin 
conjugated microbeads, and incubated and washed again. Cells were resuspended in 1 
mL depletion buffer and passed through a 30µm nylon mesh into the separation column. 
Columns were washed with 3x3mL depletion buffer. LT-HSCs (SLAM LSK) were stained 
with anti- c-kit, -Sca-1, -CD48, and -CD150 antibodies, as described above. 150 LT-
HSCs were sorted using a drop envelope of 1.25 using a BD Aria sorter into individual 
wells of a 96 well plate containing 100µL of StemSpan SFEM (STEMCELL 
Technologies, 09600) with 2% fetal bovine serum (FBS) (SAFC Biosciences, 12103C-
500mL). Competitor cells were added directly to each well in 50µL of PBS and then 
transplanted as described above. HSPCs (LSK) for in vitro assays were pre-enriched 
and sorted into the same media in 1.7mL tubes using the MoFlo Astrios EQ on the 
“purify” setting.  
 
Bone Marrow Transplant (BMT) 
Total bone marrow or sorted LT-HSCs (CD150+CD48-c-kit+Sca1+Lin-) from donor mice 
were mixed with 3x105 freshly isolated competitor (B6.SJL) cells and injected retro-
orbitally into lethally-irradiated (10Gy, split dose, Orthovoltage Precision X-Ray) F1 
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recipient mice. At 4, 8, 12 and 16 weeks post transplantation, peripheral blood of 
recipients was analyzed for donor reconstitution in myeloid, T- and B- lineages by flow 
cytometry. At 16 weeks post transplant, recipients were sacrificed and donor 
reconstitution in various HPSC compartments was analyzed using flow cytometry. BM 
cells from primary transplants were harvested and 2 million cells were injected into each 
secondary recipient. Tertiary transplants were similarly performed.  
 
pI:pC 
Mice were injected with 5 mg/kg pI:pC (InvivoGen) i.p. twice weekly for 4 weeks. On day 
28, BM cells were isolated and HSCs were quantified by FACS. One or two million total 
bone marrow from pI:pC treated mice was transplanted into each lethally-irradiated 
recipients. 
 
Colony Forming Assay 
Total BM or sorted LSK were plated onto M3434 semi-solid methylcellulose media 
(STEMCELL Technologies). Plates were seeded in triplicate and colonies were counted 
7 days after plating. For transient drug treatment, freshly sorted LSK were plated in 
Mitomycin C (MMC) (Sigma) as indicated for 4 hours, then washed and plated in M3434 
media and counted as described.  
 
Liquid culture of primary HSPCs and splenic B cells 
	36	
	
Sorted LSK were cultured in 96 well plates containing 100µL StemSpan supplemented 
with 10% FBS and 1% penicillin/streptomycin (Life Technologies, 15140-122), 1% L-
glutamine (Life Technologies, 25030-081), 100µM β-mercaptoethanol (Sigma, M7522), 
10 ng/mL murine TPO (Peprotech Inc, 315-14), and 50 ng/mL murine SCF (Peprotech 
Inc, 250-03). Cells were seeded at a density of 100,000/mL in triplicate and maintained 
at less than 1 million/mL throughout culture by subculture into fresh media. Viable cells 
were counted using a Hemacytometer (Hausser Scientific, 1475) and viability dye 
Trypan Blue (STEMCELL technologies, 07050). Cell number was recorded at day 5, 7, 
and 14 of culture. For culture in MMC, cell culture media was supplemented with fresh 
MMC when cells were subcultured. 
 
Splenic B cells were cultured in 6 well plates containing 2.5mL RPMI (Gibco, 31800-022) 
supplemented with 10% calf serum (HyClone, SH30072.03), 1% penicillin/streptomycin, 
1% L-glutamine, 1% nonessential amino acids (Life Technologies, 11140-050), 1% 
sodium pyruvate (Life Technologies, 11360-070), 50 µM β-mercaptoethanol, 5 ng/mL 
murine IL-4 (Life Technologies, PMC0045), RP105 (BD Pharmingen, 552128), and 25 
µg/mL LPS (Sigma, L4391). 
 
Cell Cycle and Apoptosis assays 
Cell cycle analysis on proliferating cells in vitro was performed using a BrdU kit (BD 
Biosciences, 559619). Cells were exposed to BrdU for 30 minutes and BrdU 
incorporation was assessed according to manufacturer’s instructions. For analysis of 
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apoptosis, cells were incubated with anti-Annexin V antibody (Biolegend cat 556420) in 
Annexin V binding buffer (BD Biosciences, 556454) for 15 minutes. Cells were then 
stained for viability by incubation with 7-AAD (BD Biosciences, 559925). Both BrdU and 
AV staining data was acquired using a BD Canto flow cytometer and FACS DiVa 
software and analyzed using FlowJo v8.7 for MAC.  
 
Cell cycle analysis on HSPCs from BM was performed with freshly isolated HSPCs. Lin-
depleted BM cells were stained for HSPC markers, then fixed and permeabilized 
followed by staining with anti-Ki-67-APC antibodies. Cell cycle analysis is performed 
along with DAPI staining for DNA content and assessed on a BD Fortessa flow 
cytometer. 
 
Metaphase spreads 
Splenic B cells or LSK were cultured for 3 or 7 days respectively, and then treated with 
0.5 µM Nocodazole (Calbiochem, 487928) for three hours to arrest in metaphase. Cells 
were incubated in 75mM potassium chloride (Sigma P9541) at 37°C for 20 minutes to 
swell cell volume, and subsequently fixed with 3:1 methanol: acetic Acid for 10 minutes 
on ice. Metaphase spreads were then prepared by dropping cells onto methanol-washed 
positively charged slides (Globe Scientific Inc 3591W). Slides were stained with Giemsa 
stain and sealed. Images of 100-150 metaphase spreads from 4-6 individual animals 
were captured using 100x objective, and chromosomal breaks and radial chromosomes 
were visually counted using FIJI software. 
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DNA fiber assay 
DNA fiber assay was performed similarly to published protocols 17,29. Splenic B cells or 
sorted LSK were cultured for 3 days then replicating DNA was labeled by a 30 minute 
pulse with 50µM IdU (Sigma I7125-5G) followed by a 30 minute pulse with 250µM CldU 
(Sigma C6891-100MG). Cells were washed then treated with HU (Sigma H8627) (4mM 
for spleen B cells and 2mM for BM HSPCs) for three hours. Cells were counted, and 
resuspended to a concentration of 2.5x105/ mL in PBS, then mixed 1:1 with unlabeled 
cells. 2.5µL of the cell suspension was mixed with 7.5 µL of lysis buffer (200 mM 
TrisHCL pH 7.4, 50 mM EDTA, 0.5% SDS) directly on positively charged slides and 
incubated for eight minutes at room temperature. The slides were then tipped to 30° and 
dried. Slides were fixed in 3:1 methanol:acetic acid overnight, then rehydrated in PBS. 
DNA was denatured using 2.5M HCl for one hour at room temperature, followed by 
washes in PBS to renormalize pH. Slides were blocked in 2% BSA, 0.1% Tween 20 PBS 
for one hour, then incubated with primary and secondary antibody for 2.5 hours and one 
hour at room temperature, respectively. DNA fibers were captured using 60x objective 
on a Nikon Eclipse 80i fluorescent microscope and quantified using FIJI software. 
 
Statistical analysis  
For all cell culture and BMT experiments, two-tailed Student’s t-tests were performed. 
Graphs are presented as mean ± SEM. For metaphase analysis and DNA fiber labeling, 
statistical comparisons were made using one-tailed ANOVA and Tukey test in PRISM 
software. The P value of less than 0.05 will be considered statistically significant. 
	39	
	
 
2.4 Results 
 
Lnk deficiency fully restores phenotypic HSCs in Fancd2-/- mice 
Mouse models of FA recapitulate cellular DNA repair defects and impaired HSPC 
function. Mice deficient for FancD2, a central component of the FA signaling pathway, 
are reported to have an ~50% reduction in HSPCs as indicated by Lineage-Kit+Sca1+ 
(LSK) cells27,30. However, the long-term (LT-) HSCs are only about 5% of the LSK 
fraction. To further pinpoint the defects in various HSPC compartments, we utilized a 
panel of cell surface markers to differentiate HSCs from multipotent progenitors (MPPs). 
Our studies reveal that Fancd2-/- mice on a pure C57/B6J background exhibit a 50% 
reduction in MPPs while the phenotypic HSCs are trending lower than wildtype (WT) 
(Fig. 1). Notably, loss of Lnk fully restored phenotypic HSCs in Fancd2-/- mice as defined 
by SLAM marker (CD150+CD48-LSK)31, or CD34-Flk2-LSK 32 markers, or the most 
stringent and current markers for LT-HSCs (CD150+CD48-CD34-Flk2-LSK)33,34 (Fig. 
1A-C, and Suppl. Fig. 1A). In fact, Fancd2-/-;Lnk-/- double mutant mice had more 
phenotypic HSCs that WT animals (Fig. 1A-C and Suppl. Fig. 1A). 
 
Lnk deficiency rescues the reconstitution defects in Fancd2-/- BM cells 
To assess if Lnk deficiency rescues the functional defects in Fancd2-/- BM cells, we 
transplanted a graded number of unfractionated BM cells into lethally-irradiated 
recipients. Fancd2-/- BM cells showed markedly compromised reconstitution in bone 
marrow transplantation (BMT) assays (Fig. 1D) consistent with previous reports, 
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although the phenotypes we observed on the pure B6 background is more severe than 
previous reports on mixed background 27,30. Strikingly, the reconstituting ability of 
Fancd2-/;-Lnk-/- BM cells was restored to WT levels (Fig. 1D). To test the self-renewal 
ability of HSCs, we performed serial BMTs. Lnk deficiency largely restored HSC self-
renewal in Fancd2-/- BM cells, albeit slightly inferior to WT cells (Fig. 1E-G and suppl. 
Fig, 1B). Fancd2-/- BM cells had near zero reconstitution in the transplants, underscoring 
the profound functional defects of FA cells as well as the significance of the rescue by 
Lnk deficiency. Of note, none of the serially transplanted mice developed leukemia. Nor 
did we observe any malignancy in cohorts of Fancd2-/-;Lnk-/- mice by 12 months of age 
(data not shown). 
 
Lnk deficiency restores HSC functions in Fancd2-/- mice 
Since Fancd2-/-;Lnk-/- double mutant mice have an increased phenotypic HSC number as 
assessed by cell surface markers, total BM transplants might reflect the number rather 
than the functions of HSCs. Thus, we purified HSCs through Fluorescence- activated 
cytometric sorting (FACS) and injected them into irradiated host animals. Our data 
showed that Fancd2-/- HSCs had a cell-intrinsic defect in reconstituting the hematopoietic 
system, while Lnk deficiency rescued the HSC functional defects associated with FA 
(Fig. 1H). 
 
Lnk deficiency does not restore HSC quiescence in Fancd2-/- mice  
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We reported previously that Lnk-/- HSCs are more quiescent22, which protects HSCs from 
regenerative stress. In contrast, FA-deficient HSPCs show decreased quiescence and 
compromised self-renewal 27,30. It is plausible that the rescued HSC compartment in 
double mullizygous mice simply reflects an accumulating quiescent HSC population. To 
address this possibility, we quantified in vivo cell cycle kinetics in HSPC subsets. We 
found that Lnk deficiency does not restore HSC quiescence in Fancd2-/- mice (Fig. 1I-J). 
Thus, the rescue of Fancd2-/- HSC homeostasis and activity is not due to protection of 
HSC quiescence. Rather, Fancd2-/-;Lnk-/- HSCs do proliferate. 
 
Lnk deficiency does not rescue MMC hypersensitivity in Fancd2-/- BM progenitors  
The hallmark of FA in humans is the hypersensitivity to ICL-inducing reagents. This 
molecular feature is recapitulated in all FA mouse models. To explore the mechanisms 
by which Lnk deficiency ameliorates HSPC defects associated with FA, we first 
examined the MMC sensitivity of BM progenitor cells. Using both liquid culture growth 
assay and clonogenic survival assays, we found that both Fancd2-/-Lnk-/- and Fancd2-/- 
BM progenitors are strongly sensitive to MMC in comparison to WT progenitors (Fig. 2). 
Lnk-/- single KO BM cells show similar MMC sensitivity to that of WT (data not shown). 
Thus, Lnk does not appear to play an overt role in ICL repair. 
 
Lnk deficiency rescues ex vivo growth and restores genome stability of Fancd2-/- 
progenitors 
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BM progenitors from BMF syndromes show growth retardation even in the absence of 
DNA damage-inducing reagents 35. Thus, we subjected BM progenitor cells from 
Fancd2-/- mice to liquid cultures in the presence of cytokines. Indeed, Fancd2-/- HSPCs 
showed progressive loss of growth ability in comparison to that of WT or Lnk-/- HSPCs 
(Fig. 3A). Importantly, Lnk deficiency rescued the growth disadvantage of Fancd2-/- BM 
cells as well as colony-forming-unit (CFU) progenitors (Fig. 3B). FA cells are observed 
to have a higher rate of apoptosis 36.  Indeed, we observed the percentage of apoptotic 
cells was doubled in Fancd2-/- culture relative to WT (Fig. 3C), but the cell cycle 
progress remain little perturbed (Suppl. Fig. 2). Importantly, the percentage of apoptotic 
cells in DKO was on par with WT (Fig 3C), indicating that Lnk deficiency ameliorates the 
survival defect of Fancd2-/- cells.  
 
The increased apoptosis in Fancd2-/- cells is attributable to a higher level of genome 
instability, and suppression of genomic instability is a major role of the FA pathway. 
Thus, we examined chromosomal abnormality in ex vivo cultured progenitors. We 
arrested cultured BM HSPCs in mitosis with nocodazole and subsequently prepared 
metaphase spreads as described 37. At least 30 metaphases from each sample were 
scored for the presence of sister chromatid breaks, gaps and radial chromosome 
aberrations, which are hallmarks of ICL repair deficiency in FA. Chromosomal 
abnormalities were elevated in Fancd2-/- cells as expected, which was partially rescued 
by Lnk loss (Fig. 3D-E). Primary splenic B cells have been widely used to study 
molecular and cellular defects in FA mouse models 17. To assess if Lnk deficiency 
restores genome stability in cell types other than BM HSPCs, we examined 
chromosomal aberrations in B cells. We found that in these cells, genome instability in 
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Fancd2-/- is also significantly elevated relative to WT, while Lnk deficiency restored it to 
WT levels (Fig. 3E and suppl. Fig. 3), reinforcing our conclusion and extending the 
effect of Lnk deficiency to cell populations beyond HSPCs. Together these results 
showed that Lnk deficiency rescues growth and apoptotic defects and reduces genome 
instability in the Fancd2 deficient cells. To our knowledge, this is the first genetic model 
of reduced genome instability in FA cells. 
 
Lnk deficiency restores HSPC function upon physiological stress-induced 
proliferation 
FA cells are known to be impaired by the damage resulting from physiological stress, 
such as forced proliferation induced by transplantation and by administration of 
polyinosinic:polycytidylic acid (pI:pC) 8. To determine whether Lnk deficiency rescues 
Fancd2-/- HSPC function in context of endogenous replication stress, we induced HSPC 
proliferation in vivo by repeated treatment with pI:pC. We then examined phenotypic 
HSC by FACS and HSC functions by BMT (Fig. 4A). Fancd2-/- mice exhibited a 
reduction in HSCs upon pIpC stress compared to WT, while Lnk-/- mice had more HSCs 
than WT (Fig. 4B-C). Importantly, Lnk deficiency restored HSC numbers in Fancd2-/- 
mice (Fig. 4B-C). Functionally, Fancd2-/- BM cells repopulated to a very limited extent 
(Fig. 4D and suppl. Fig, 4). Remarkably, BMs from double nullizygous mice 
repopulated on par with WT (Fig. 4D and suppl. Fig, 4), indicating robust LT-HSC 
activity. Taken together, these data show that Lnk deficiency preserves HSC function in 
Fancd2-/- mice upon physiological replication stress.  
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Lnk deficiency stabilizes replication fork upon replication stress in Fancd2-/- 
progenitors  
Cells deficient in FA/BRCA are sensitive to replication poisons, such as hydroxyurea 
(HU) or poly(ADP-ribose) polymerase (PARP) inhibitors. To investigate a potential role 
of LNK in replication stress, we first treated freshly isolated HSPCs with PARP inhibitor 
AZD881. PARP is required for Mre11 localization to stalled forks, and its loss protects 
against genome instability in Brca mutant backgrounds 17,38,39. Fancd2-/- HSPCs showed 
a marked reduction in CFU progenitors upon PARPi, and Lnk deficiency rescued 
progenitors’ clonogenic ability in Fancd2-/- mice (Fig. 5A). In contrast, Lnk deficiency 
failed to rescue clonogenic ability of Fancd2-/- HSPCs upon MMC treatment (Fig. 5A). 
Thus, our data suggest that Lnk deficiency alleviates replication stress but not ICL-
induced genotoxic stress associated with FA. 
 
To examine the mechanisms by which Lnk loss ameliorates replication stress associated 
with FA, we treated BM progenitors with HU and examined the stabilization of stalled 
replication forks by single-molecule DNA fiber analysis 29. Replication tracts of log-phase 
cultured HSPCs were pulse labeled with IdU and CldU sequentially before replication 
fork stalling by HU (Fig. 5B). Single DNA fibers were spread onto microscope slides 
before immunofluorescence staining with antibodies against IdU and CIdU to measure 
relative fork length (CidU/IdU ratio). The relative shortening of the IdU tract after HU 
treatment serves as a measure of replication fork degradation. WT HSPCs as well as 
splenic B cells showed a mean IdU/CldU tract ratio close to 1 (Fig. 5B-D). However, 
Fancd2-deficient cells exhibited a 30–45% reduction in the relative IdU tract length (Fig. 
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5B-C). Importantly, we discovered that loss of Lnk protected stalled replication fork from 
degradation upon replication stress in Fancd2-/- progenitors as well as B cells (Fig. 5B-
C). Furthermore, we demonstrated that Lnk deficiency conferred resistance to HU in 
clonogenic survival of HSPCs (Fig. 5G). 
 
Cytokine-JAK2 signaling is important in stabilizing stalled replication forks  
Since LNK negatively regulates the cytokine receptor-associated JAK2 kinase, we next 
asked whether its role in fork protection was cytokine signaling-dependent. Since BM 
HSPCs dependent upon cytokines for their survival in culture, we were unable to 
withdraw cytokines from BM culture. By removing IL-4 from the splenic B cell culture, it is 
possible to evaluate the role of cytokine-JAK signaling in isolation while still providing 
mitogenic stimuli to proliferating B cells through Toll-like receptor signaling. In these 
conditions, Lnk deficiency failed to rescue Fancd2- null B cells from replication 
degradation upon HU stress (Fig. 5E), suggesting that cytokine/JAK signaling plays a 
role in replication fork stabilization. 
 
We next attempted to decipher the signaling pathways that contribute to replication fork 
stability in Lnk null cells. LNK is a cytoplasmic adaptor protein that is not known to 
associate with chromatin. We previously reported that Lnk deficiency potentiates JAK2 
activation in HSPCs, which in part accounts for its role in HSC self-renewal22-24,28. To 
define the role of JAK2 in replication fork stability, we subjected WT and Lnk-/- HSPCs to 
JAK inhibitors (Ruxolitinib) and examined its effects on replication fork stability. We 
found that WT HSPCs were sensitive to JAKi in stabilizing stalled replication fork, while 
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Lnk-/- HSPCs were more resistant to JAKi (Fig. 5F). Furthermore, MRE11 inhibitor Mirin 
was able to rescue replication fork degradation in WT HPSCs upon JAK inhibition. Our 
data suggest that JAK signaling contributes to replication fork stabilization in HSPCs 
through MRE11-mediated nuclease activity.  
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2.5 Discussion 
 
This report demonstrated that loss of Lnk restores FA HSPC functions by alleviating 
replication stress. To our knowledge, these findings represent a rare in vivo example of 
genetic suppression of FA-associated HSPC defects. There are very few examples of 
animal models in which there are elevated HSC numbers and function40. Understanding 
how Lnk deficiency imparts these remarkable HSC properties will likely advance our 
understanding of stem cell biology and offer insights into strategies for the treatment of 
FA and other BMF diseases in general. 
 
We show that Lnk deficiency increases phenotypic and functional HSCs in Fancd2-/- 
mice. It has been showed recently forced proliferation in vivo by repeated pIpC treatment 
leads to HSC exhaustion and BMF in FA mice. We found that Lnk deficiency mitigates 
HSC exhaustion upon physiological stress. Our ex vivo growth results are also 
consistent with the in vivo BMT data, as reconstitution of myelo-ablated animals is a 
form of “forced” proliferation. Furthermore, we showed that Lnk deficiency does not 
protect HSC quiescence in FA, rather it allows Fancd2-/- HSPCs to proliferate and self-
renew. Previous work demonstrated that p53 activation contributes to the HSPC decline 
and BMF in FA9. However, p53 levels remain unchanged and p53 signaling remains 
intact in Lnk-/- cells (data not shown), suggesting that the rescue of FA by Lnk deficiency 
cannot be attributed to p53 inhibition. While the survival of Fancd2-/- cells can be 
improved by inactivation of apoptotic signaling with deletion of p53 9 or inflammatory 
signaling with inactivation of TNFa signaling41, the genomic instability in Fancd2-/- cells 
has not been demonstrably suppressed by these pathways. We showed here that Lnk 
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deficiency mitigates replication stress-incurred chromosomal aberrations in FA mice and 
prevents HSPCs attrition without incurring leukemic transformation. Understanding 
mechanisms by which Lnk deficiency suppresses FA phenotypes will facilitate 
development of strategies that have the dual benefit of ameliorating BMF and 
simultaneously reducing genome instability. 
 
Our studies raise the question on the cause of stem cell attrition and BMF in FA patients. 
It has been suggested that endogenous aldehydes, in the forms of acetaldehydes from 
cellular lipid peroxidation and formaldehydes from histone, DNA, and RNA 
demethylation, leads to ICL DNA damage 6,42. FA patients and mice are thus more 
sensitive to deficiencies in the aldehyde detoxification enzymes, such as Aldh2 and 
Adh5 6,42. We found that deficiency in Lnk protects stalled replication forks from 
degradation and rescues the survival and stabilizes genome integrity of Fancd2-/- HSPCs 
without restoring ICL-induced DNA repair. Therefore, our results imply that replication 
stress may be a more important mechanism for HSC attrition and BMF in FA than 
previously appreciated. Lnk deficiency increases stem cell fitness and alleviates HU-
incurred replication stress. This translates to a superior HSC self-renewal and serial 
transplantability upon forced proliferation in vivo or in vitro. We speculate this DNA 
repair-independent mechanism is a more probable cause of HSC exhaustion in FA, 
which is illustrated by the rescue of Lnk deficiency in mitigating replication stress. 
 
We show that Lnk-/- HSPCs are hypersensitive to MMC-induce DNA damage, indicating 
that LNK does not play an overt role in ICL repair. A more recently described role for FA 
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proteins is in replication fork stability 15. The FA/BRCA pathway is recruited to stalled 
replication forks and is essential in preventing fork destabilization and resection by 
Mre11 nuclease 15,16. Without fork stabilization by RAD51, Mre11 degrades stalled 
replication forks, results in double stranded breaks, which can lead to chromosomal 
rearrangements and genome instability. It has been shown recently that protection of 
nascent DNA from degradation provides a mechanism that can promote synthetic 
viability in Brca-deficient cells and causes drug resistance in Brca-deficient cancers 
without restoring HR at DSBs 17. These results suggest that defects in replication fork 
stabilization upon replication stress rather than DNA repair deficiency in FA/BRCA 
mutated tumors contribute to genome instability and transformation to cancer. We found 
that Lnk deficiency rescues fork stability and genome instability in B cells in addition to 
BM HSPCs, suggesting a potential broad role for LNK in replication and perhaps that 
outside the hematopoietic system. 
 
LNK is a cytoplasmic adaptor protein, which is not known to associate with chromatin 
and all known associated proteins are cytoplasmic. Moreover, a recent large-scale 
proteome effort identified hundreds of proteins enriched in nascent chromatin, however, 
LNK was not among them43. Given LNK’s role in limiting cytokine signaling, we 
hypothesize that LNK regulates the activity of kinase cascades that transmit their signals 
to the nucleus to affect the expression or activity of DNA replication and repair proteins. 
Indeed, our results highlight the importance of cytokine-mediated JAK2 signaling in 
replication stress. This is the first example, to our knowledge, that cytokine/JAK signaling 
plays a role in promoting replication fork stability. Future efforts are warranted to 
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elucidate the mechanisms by which LNK-regulated JAK signaling in replication stress 
alleviation. 
 
Taken together, Lnk deficiency mitigated replication stress-incurred DNA damage in FA 
mice and prevented HSPCs attrition without incurring leukemic transformation. 
Understanding mechanisms by which Lnk deficiency suppresses FA phenotypes will 
facilitate development of strategies that have the dual benefit of ameliorating BMF and 
simultaneously reducing genome instability. Our research sheds light on the underlying 
the origin of BMF in FA patients and has implications for new therapeutic strategies. 
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2.8 Figure legends 
 
Figure 2.1: Lnk deficiency restores phenotypic and functional HSCs in FancD2-/- 
mice.  
(A-C) Quantification of various HSPC compartments by flow cytometry, Lin-kit+Sca1+ 
(LSK) HSPC population (A), LT-HSCs (CD48+CD150-CD34-LSK) (B) and MPP 
(CD48+CD150-LSK) (C) in WT, FancD2-/- (D2-/-), Lnk-/- (L-/-) and FancD2-/-;Lnk-/- (D2-/-L-/-) 
mice. (D-G) show serial transplantation of total bone marrow cells from WT, D2-/- and D2-
/-L-/- mice. A graded number of BM cells were mixed with competitors and transplanted 
into lethally-irradiated host animals. (D) Donor chimerisms in the peripheral blood of the 
recipient mice 16 weeks after transplant are shown. (E) At the end of primary transplant. 
Donor frequency in the host BM and various HSPC populations were quantified by flow 
cytometry. The 3x105 group was transplanted into secondary and tertiary recipients. 
Donor chimerism in peripheral blood after secondary transplant (F) and tertiary 
transplant (G) are shown. (H) 100 purified SLAM LSK HSCs were mixed with 3x105 
competitors and transplanted into lethally-irradiated recipients. Donor chimerisms in 
peripheral blood 16 weeks after transplant are shown. Each symbol represents an 
individual mouse; horizontal lines indicate mean frequencies; error bars indicate SE. p 
values determined by two-tailed student’s t-test are shown.  ns: not significant. (I-J) 
shows quantifications of cell cycle analysis of LT-HSCs (D) and MPPs (E) in mice of 
different genotypes. **: p<0.01 compare to WT, two-tailed student’s t-test. 
 
Figure 2.2: Lnk deficiency does not rescue ICL hypersensitivity associated with 
FancD2 deficiency. (A) HSPCs were cultured in different concentrations of MMC for 7 
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days. Total (right) and relative cell numbers to untreated cells (left) are shown. Statistical 
analysis using two-tailed student’s t-test of comparisons among untreated and MMC-
treated cells within each genotype are indicated. (B-D) Fresh BM cells were plated in 
semi-solid methylcellulose media containing various concentrations of MMC and 
assessed for progenitors of myeloid (B), B cell (C), and erythroid lineages (D). Relative 
colony forming units relative to untreated are shown. * p<0.05, ** p<0.01, two-tailed 
student’s t-test,  denotes comparison between WT and D2; † p<0.05, †† p<0.01, 
denotes WT vs DKO.  
 
Figure 2.3: Lnk deficiency rescues the growth and survival defect of FancD2-/- 
HSPCs and mitigates genome instability. (A-B) HSPCs were cultured in TPO and 
SCF containing media for 14 days. (A) Cumulative cell growth at days 5, 7 and 14 is 
shown. (B) At each corresponding day of culture, cells were plated for quantification of 
colony-forming progenitors. Cumulative progenitor cell numbers were calculated and 
plotted. P values indicate two-tailed student’s t-test. (C) On day 7, percentage of 
apoptotic cells was assessed by Annexin V staining and shown. For panels A-C one 
representative experiment of three independent replicates is shown. (D-F) HSPCs 
cultured 7 days (E) or splenic B cells cultured 3 days (F) in cytokines were assessed for 
chromosomal aberrations. (D) shows examples of chromosomal breaks (arrows) and 
radial chromosomes (arrowhead) scored on metaphase spreads. Quantifications of 
mean aberrations for 100-150 metaphase spreads from 4-6 animals are shown, and 
error bars indicate SE. Comparisons among all 4 genotypes were calculated by one-way 
ANOVA are shown for each graph. p-values using Tukey’s t-test for each indicated 
comparison pair are shown.   
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Figure 2.4: Lnk deficiency rescues HSC defects associated with FA upon forced in 
vivo proliferation. Proliferation of HSPCs in vivo was induced by pI:pC injection. (A) 
depicts a schematic overview of pI:pC injection. Mice were injected i.p. with 5mg/kg 
pI:pC twice per week over four weeks, followed by analysis for HSPC frequency and 
function in bone marrow at day 28. LT-HSC frequency determined by SLAM LSK (B) or 
CD34-Flk2-SLAM LSK (C) marker schemes is shown. Bars indicate mean of frequencies 
from four to six mice, and error bars indicate SE.  Statistics were calculated by two-tailed 
student’s t test. (D) Two million total BM cells from treated mice were mixed with 3x105 
competitors and transplanted into lethally-irradiated host animals. Donor chimerism in 
peripheral blood of recipients 16 weeks after transplant is shown. Each symbols 
represents an individual recipient animal, horizontal bars represent the mean of each 
group. p values from two-tailed students’ t-test are shown. 
 
Figure 2.5: Lnk deficiency stabilizes stalled replication forks in FancD2-/- HSPCs 
through cytokine-JAK2 signaling. (A) Freshly-isolated HSPCs were treated for 4 
hours with MMC or AZD881 (PARP inhibitor), and subsequently plated in semi-solid 
methylcellulose media. Colony forming progenitor numbers relative to the vehicle-treated 
group (mean± SE) were enumerated and graphed. ** p<0.01, two-tailed student’s t-test. 
(B) The top panel shows the experimental overview of the fork protection assay. (B-C) 
Bone marrow HSPCs were subjected to fork protection assay. The frequencies of 
different replication tract ratios are plotted (B). (C) The distribution of CldU/IdU fiber 
ratios is shown with the horizontal lines indicating median fiber ratios, and the medians 
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shown at the bottom of the graph.  (D-E) B cells were cultured in RP-105 and LPS with 
(d) or without IL-4 (E), and the median of fiber ratios are shown. (F) HSPCs were 
cultured in the presence of 1µM JAK2 inhibitor ruxolitinib (JAKi) or vehicle alone (Veh) 
and the distributions of fiber ratios are shown. In panels (B-F) each individual symbol 
represents one CldU/IdU labeled fiber and the horizontal line indicates the mean of each 
group. The mean of each distribution is written under each plot. Statistical significance of 
each set of conditions was calculated using one-way ANOVA and comparisons between 
individual groups were calculated using Tukey’s t-test. (G) Freshly-isolated HSPCs were 
treated for 4 hours with HU and colony forming potential was assessed. Representative 
of 4 independent experiments are shown. Statistics were calculated using two-tailed 
student’s t-test. 
Figure 2.6: Model. TPO signaling impacts FANCD2 function at stalled replication 
forks.
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Supplemental Figures: 
Figure S1: Lnk deficiency restores phenotypic HSCs but not MPPs in Fancd2-/- 
mice. (A) Quantification of various HSPC subsets by flow cytometry using the CD34 and 
Flk2 surface marker scheme: LT-HSCs (CD150+CD48-CD34-Flk2-LSK), HSCs (CD34-
Flk2-LSK) and MPP (CD34+Flk2+LSK). (B) Quantification of various HSPC subsets in 
BM of transplanted mice by flow cytometry. P values are calculated using two-tailed 
student’s t-test. 
 
Figure S2: Lnk deficiency does significantly alter cell cycle status in Fancd2-/- 
HSPCs in a short-term ex vivo cell culture. Quantification of cell cycle status in 
HSPCs using Ki67 and DAPI after seven days in culture. Bars indicate mean and error 
bars indicate SE. *: p<0.05 compared to WT, student’s t-test. 
 
Figure S3: Lnk deficiency partially mitigates genome instability after long-term 
culture in Fancd2-/- HSPCs. Quantification of chromosomal aberrations by metaphase 
spread in HSPCs after 10 days of culture. Results from 100-150 metaphase spreads of 
4-6 animals are shown. Bars indicate mean and error bars indicate SE. p-values using 
student’s t-test for each indicated comparison pair are shown. Comparisons among all 4 
genotypes calculated by one-way ANOVA is also shown.  
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Figure S4: Lnk deficiency restores Fancd2-/- HSPCs function after forced in vivo 
cell proliferation. Peripheral blood reconstitution by donor derived cells 16 weeks after 
transplant of one million total BM from pI:pC –treated mice is shown. Each symbols 
represents an individual recipient animal, horizontal bars represent the mean of each 
group. p values from two-tailed students’ t-test are shown. 
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3.1 Abstract 
Hematopoietic stem cells (HSCs) are rare cells in the bone marrow that continually 
generate and replenish all hematopoietic lineages in the blood throughout life and are 
distinguished by their multilineage differentiation and self-renewal capacities. Adult bone 
marrow HSCs possess a unique cell cycle status, which is termed quiescence, and 
infrequently exit quiescence to proliferate and self-renew. Self-renewal is defined as the 
inheritance of HSC properties by one or both daughter cells and is regulated by HSC 
division kinetics. 
 
Deficiency of the adaptor protein LNK, a negative regulator of the Thrombopoietin 
signaling pathway in HSCs, results in a 10-fold expanded HSC pool. Lnk-/- HSCs have 
superior reconstitution potential, enhanced self-renewal and do not exhaust prematurely. 
This augmentation in HSC function is due, in part, to an increased propensity for HSC 
self-renewal in Lnk-/- HSCs. This property has been observed at a single cell level in 
vitro, but it is unclear how LNK deficiency influences self-renewal propensity.   
 
Using a label retention model that tracks HSC division in vivo, we demonstrate a 
divisional heterogeneity in a highly enriched stem cell population. We demonstrate that 
HSC function is inversely correlated with each in vivo division and that Lnk deficiency 
both enhances the stem cell properties of undivided HSCs, and increases the frequency 
of bona-fide HSCs in subsets of cells that have divided several times in vivo. Genome-
wide expression profiling reveals a transcriptional status correlated with active RNA 
synthesis and signal transduction in undivided cells, and an increase in DNA synthesis 
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and mitotic machinery as cells accrue in vivo divisions. We identify progressive changes 
in expression of several genes related to self-renewal, which may be targets of 
enhanced Tpo signaling in Lnk-/- HSCs. Additionally, our study uncovers that LNK 
deficiency retards changes in cell surface expression of several HSC-associated 
proteins, suggesting a transcription-independent role for LNK deficiency in regulating 
self-renewal. 
 
Taken together our findings provide an unprecedented view of the relationship between 
in vivo HSC division and self-renewal and illuminate several potential mechanisms 
involved in self-renewal that might be impacted by Lnk deficiency.
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3.2 Introduction	
Hematopoietic cells are generated and maintained throughout life by a relatively rare 
population of stem cells. There is an inverse relationship between the frequency of 
division and the long-term repopulating capacity of HSCs (LT-HSCs). The exact 
mechanisms behind this relationship between the frequency and fate determinants of 
division remain poorly understood; however, they are immensely important as they 
regulate the size of the HSC pool, and indirectly, the ability of HSCs to maintain a 
constant, homeostatic hematopoietic supply. 
 
Lnk-/- HSCs have enhanced self-renewal capacity. In vitro, Lnk-/- HSCs show a 
propensity towards symmetric self-renewing divisions 1 but it has not been possible to 
study this propensity on a single cell level in vivo. Additionally, it is not well understood 
how Lnk deficiency impacts the propensity for self-renewal in HSCs.  
 
In this manuscript, we investigate HSC self-renewal in vivo using the M2R-tTA; H2B-
GFP mouse model, in which H2B is fused with GFP and its expression is induced in 
response to doxycycline administration (Fig 3.S1A). Virtually all cells are labeled during 
a six-week pulse period, and upon doxycycline withdrawal, GFP signal is diluted two-fold 
with each division as each cell inherits half of the labeled H2B. Long-term chase 
experiments have identified HSCs as those cells that retain the GFP label 2,3. By using a 
relatively short chase period, we hoped to catch a population of stem cells with sufficient 
heterogeneity, such that there would be a mix of true LT-HSCs and some ST- or non-
HSCs. We anticipated that undivided cells – the d0 population – would contain almost 
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exclusively HSCs. As cells undergo division we expected to see a dilution in 
transplantation capacity such that by d5+ there would be few, if any, HSCs.  
 
Naturally, the choice of cell population would be very important – too many or too few 
HSCs and we would not catch this heterogeneity. We therefore chose to study HSC self-
renewal in SLAM LSK. First, the SLAM LSK HSC population has been extensively 
characterized 4,5. Second, SLAM LSK cells represent a significant portion of all label-
retaining cells. As previously shown, label-retaining cells are enriched by markers 
associated with HSCs. The stem and progenitor compartment defined by LSK markers 
considerably enriches for label retaining cells relative to Lin-c-kit+ alone. SLAM LSK 
further enriches for label retaining cells and represents approximately half of all label-
retaining cells (Fig 3.S1B). Finally, since 1 in every 3 cells in SLAM LSK is a LT-HSC 4, 
there is a high likelihood this population contains a mix of cells suitable to our study. We 
hypothesized that division status might further stratify LT-HSCs from other cells within 
SLAM LSK. To this end, we were encouraged to find that SLAM LSK cells are comprised 
of a heterogeneous cell population with respect to division.  
 
Here we show that HSCs in SLAM LSK are further dissected functionally from early 
progenitors and non-HSCs by in vivo division status, and demonstrate the propensity of 
Lnk-/- HSCs to self-renew in vivo using this system. We highlight trends with division that 
correlate with self-renewal propensity and identify transcriptional changes genome-wide 
expression in Lnk-/- SLAM LSK across divisions, which may shed light on how Lnk 
deficiency promotes self-renewal.
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3.3 Results 
HSCs exist in a continuum of repopulating capacity over in vivo division and this 
continuum is skewed by LNK deficiency  
Given the inverse relationship between division and self-renewal capacity, we were 
curious to know whether division status could explain the functional heterogeneity 
observed within the SLAM LSK compartment. To address this question, we first 
visualized the division history of SLAM LSK using FACS. After four weeks of chase, 
SLAM LSK cells exist as heterogeneous population distributed by their division history 
(Fig 3.S1B). We were able to discern seven distinct division states (division 0 – 6+). We 
hypothesized that the number of functional LT-HSCs would be decreasing with in vivo 
division. To test this, we sorted individual division subsets of SLAM LSK (d0, d2, d4, or 
d5+) and assayed their repopulating capacity from WT and Lnk-/- donors by competitive 
transplant. Indeed, in both genotypes, we observed a decreasing trend in donor 
reconstitution in peripheral blood with division, indicating that later divisions contained 
fewer functional LT-HSCs than earlier ones (Fig 3.1A). 
 
We then examined repopulation between WT and Lnk-/- cells. Lnk-/- cells repopulated 
recipients significantly better than their WT counterparts within each division subset (Fig 
3.1A). Strikingly, recipients of d5+ WT cells did not reach 1% peripheral donor chimerism 
(the cutoff for functional HSCs) 6 7 1 8, while 4/5 recipients of d5+ Lnk-/- cells did (Fig 
3.1A), indicating that at least 1/100 d5+ SLAM LSK is still a functional HSC in Lnk-/- 
mice. This was more evident in secondary transplant, where 3/5 recipients of d5+ Lnk-/- 
cells repopulated robustly. Additionally, secondary recipients of d4 Lnk-/- cells had donor 
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chimerism on par with those of d0 cells, while recipients of WT counterparts were 
significantly less reconstituted, on average (Fig 3.1B). Individually, only 2/5 recipients 
showed robust reconstitution in the WT group, in contrast with 7/7 recipients of Lnk-/- 
cells. Together this data indicates the presence of bona fide HSCs capable of self-
renewal in d4 and d5+ subsets of Lnk-/- SLAM LSK.   
 
Secondary transplant and phenotypic HSCs frequency in primary transplant recipient 
indicate HSC self-renewal. To look directly at this, we quantified the donor SLAM LSK in 
bone marrow of primary recipients. The donor SLAM LSK frequency of Lnk-/- cells 
showed a marked expansion over WT counterparts. Additionally, Lnk d0 and d2 SLAM 
LSK expanded significantly over WT d0 cells and expansion was on par between WT d0 
in Lnk-/- d4 subsets (Fig 3.1C). The expansion was most evident in d2 and d4 recipients, 
in which Lnk-/- cells expanded 8.11x and 13.4x over their WT counterparts, respectively, 
exceeding the fold expansion by d0 cells.  
 
Another important metric of HSC function is lineage choice. The predominant LT-HSC 
subtype is the β-HSC, which produces a B-cell heavy lineage distribution 9. Single 
lineage repopulation indicates a committed progenitor, while myeloid skewing indicates 
HSC subtypes that are either partially committed or nearing exhaustion 9. We therefore 
next assayed the lineage distribution of primary and secondary transplant recipients. In 
primary recipients, we found no significant differences in lineage distribution through d4 
in both genotypes (Fig 3.1D). In division 5+ of Lnk-/- cells, there was a T-cell skew, 
indicating some lineage-committed cells (Fig 3.1E). Similarly, in secondary transplant, 
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though there was significantly more myeloid skewing than in primary transplant, there 
wasn’t a significant lineage bias until d5+ in recipients of Lnk-/- cells. Therefore, Lnk 
deficiency slants HSCs along the continuum towards self-renewal and reconstitution. 
 
In vivo division imparts cell intrinsic changes to HSCs 
A distinguishing feature of LT-HSCs is their quiescent status, which is evident at the 
transcriptional and cellular level. In vitro, LT-HSCs are demonstrated to enter division 
later than their ST-HSC and MPP counterparts, resulting in a net proliferative delay, 
which may help prevent unnecessary proliferation and depletion of LT-HSCs. This delay 
has been attributed to LT-HSCs exiting quiescence later, having to activate 
transcriptional and translational machinery for responsiveness to growth stimuli. Indeed, 
the second in vitro division occurred after the same interval regardless of cell identity 10 8. 
 
We asked how in vivo division history influences exit from quiescence in SLAM LSK with 
various in vivo division histories. To investigate this, we sorted single cells into wells of a 
96 well plate and manually inspected the wells every two hours over a period of 72 hours 
and scored the number of cells per well. We wanted to maximize our chances of 
observing HSCs, so we performed this assay in Lnk deficient SLAM LSK, where there 
are more HSCs than in WT SLAM LSK. To further increase our chances, we chose a 6 
week chase. We reasoned that in shorter chase times early division subsets (d0-2) are 
more likely to also include progenitors that have recently started dividing, whereas 
longer chase times would enrich for HSCs in these subsets. This is an important 
consideration since transplant only tests whether long-term repopulating activity is 
	79	
	
present in the donor cells, and is not influenced by contaminating cells. In contrast, a 
single cell division assay reads every cell in the population and therefore its composition   
is more important. Indeed, after 6 weeks a greater proportion of SLAM LSK are in 
division subsets 6+ (Fig 3.2A). However, by transplant, cells in d0, d2, and d4 
reconstitute recipients on par with cells after 4 week chase (Fig 3.2B), indicating that 
HSC distribution among subsets is similar between 4 weeks and 6 weeks of chase.  
 
Strikingly, we found a strong negative correlation between every in vivo division and time 
to first division in vitro (Fig 3.2C). Cells in d0 divided significantly later (38 hours) than 
any other subsets. In fact, there was a step-wise shortening of time to division in vitro 
with division in vivo: cells in d1 and d2 subsets divided on par with one another, and 
significantly later than those in d4 (Fig 3.2D). The net effect of this spread in time to 
division was that later division subsets produced more cells by the end of the 
observation period than earlier division subsets. This was largely owing to the difference 
in time to first division, as the rate of second division was more similar (Fig 3.2E), and 
cell death was negligible (data not shown). Taken together these data demonstrate that 
in vivo division primes HSCs towards proliferation, even after a single in vivo division. 
 
Lnk deficiency delays the exit from quiescence of undivided cells 
To study how Lnk deficiency impacts cell exit from quiescence, we performed a 4 week 
chase followed by time to first division assay on WT and Lnk-/- d0, d2 and d4 cells. Here 
a clear negative correlation between division and time to in vitro division is also evident 
(Fig 3.3A), albeit less dramatic among d2 and d4 subsets. In both genotypes, d2 and d4 
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cells divide earlier than d0 (Fig 3.3B). Interestingly, however, Lnk deficient d0 cells divide 
significantly later than their WT counterparts (38.4 vs 35.8 hours), suggesting a deeper 
quiescent status (Fig 3.3C). Strikingly, Lnk-/- and WT cells in d2 and d4 subsets divide 
on par with one another (Fig 3.3B). By the end of the observation period, there was more 
net change in growth between Lnk-/- and WT cells in d2 or d4 subsets (Fig 3.3D). Taken 
together these findings demonstrate that Lnk deficiency widens the difference in 
behavior between divided and undivided HSCs. 
 
Genome wide gene expression correlates with continuum of HSC functional states 
in vivo 
HSCs exist on a transcriptional continuum in vivo 11  and division-related processes are 
the major source of expression variation among HSCs 12. However, there has never 
been a direct study of the relationship between in vivo division history and transcriptional 
profile. We therefore set out to examine how transcription changes with in vivo division. 
To do this we profiled RNA expression in SLAM LSK across d0, d2, d4, and d5+ division 
subsets by RNAseq. We recovered high percentage (Table 3.S1) of high quality reads, 
with tight clustering between replicates, with a greater Pearson correlation distance 
between samples than between biological replicates (Fig 3.4A). We next performed 
differential expression analysis using DESeq2. 1852 genes were significantly changed 
among all comparisons, with the greatest number changed between d0 and d5 (Fig 
3.4B). Interestingly and consistently with their similar behavior in vitro, there were no 
significant expression changes between d2 and d4 (Fig 3.4B). Unsupervised clustering 
of gene expression by k-means clustering revealed four clusters: one set of genes with 
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high expression in d0 only (Cluster 1), one set gradually decreasing in expression from 
d0 to d5+ (Cluster 2), another gradually increasing (Cluster 3), and one with high 
expression in d5+ only (Cluster 4) (Fig 3.4C). 
 
To better understand the genes within each cluster functionally, we performed Gene 
Ontology (GO) analysis on each of the four clusters. We chose to display only the top 15 
enriched categories for each cluster. Cluster 1 is enriched for processes related to 
negative regulation of differentiation (GO:0051254, GO:0051241, GO:0051093) (Fig 
3.4D), consistent with previous reports of transcriptional profiles in quiescent cells 13 14. 
Interestingly, several categories related to transcription, and RNA biosynthesis and 
processing are also enriched in Cluster 1(GO:0045944, GO:0051254, GO:1902680, 
GO:1903508, GO: 0045893, GO:0010628). Given the well-documented observation that 
quiescent cells have low RNA content 15 16, it is possible that there is high turnover in 
RNA in d0 cells. This is in agreement with findings that demonstrate quiescent HSCs 
produce transcripts rich in intronic sequences and only express processing machinery as 
they activate and proliferate 17. Finally, several categories related to protein signaling are 
also enriched (GO:0006468, GO:0018193, GO:0035556, GO:0016310), indicating that 
these cells are actively engaged in signaling, potentially with the niche 18. 
 
In Cluster 2, there is enrichment in RNA processing, and cytokine and tyrosine kinase 
signaling categories (Fig 3.4D), as in Cluster 1. Notably, there is robust enrichment in 
TGFβ regulation (GO:0017015, GO:1903844), which is consistent with previous reports 
showing that TGFβ signaling promotes HSC quiescence in vivo 19. Additionally, there are 
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several categories associated with cell motility (GO:0010810, GO:0051272, GO:000147, 
GO:0030335, GO:0040017). Though contradictory at first, it is consistent with our 
unpublished observation that after the first in vitro division d0 and d2 daughter cells have 
high motility, and move apart from one another while daughters of d4 cells or after in 
vitro divisions do not. Similar observations were previously made in a study where HSCs 
were imaged every three minutes through time lapse microscopy and shown to have 
fewer cellular processes than more differentiated cells 8. 
 
In Clusters 3 and 4 the majority of enrichments fall into categories associated with DNA 
replication and cell division (Fig 3.4D). Interestingly, Cluster 3 is enriched primarily for 
RNA biogenesis, DNA synthesis and DNA repair, and this is evident transcriptionally as 
early as the d2 population. However, the strongest enrichment for actual cell division is 
in Cluster 4, which is only highly enriched in d5+. This is consistent with the decreased 
repopulating capacity that we observe in divisions 4 and 5, and underscores the pro-
proliferative, largely non-HSC composition of these populations. 
 
Gene Set Enrichment (GSEA) is a widely used independent gene expression analysis 
tool that ranks gene expression in sets against a null distribution, and can thus detect 
changes in gene expression based on whole pathways. Using GSEA, we found 
evidence of similar trends and patterns as in the cluster analysis. Relative to d0, every 
division subset showed enrichment for biosynthetic and division processes (Myc_targets, 
E2F_targets, G2M_Checkpoint), which again underscores that in vivo division poises 
cells for proliferation 20. Consistently, this trend was gradual across division subsets: 
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comparing between d2 and d5+, d5+ cells were enriched for additional gene sets related 
to active division, indicating a more robust proliferative transcriptional profile (Fig 3.4E). 
 
Taken together, our transcriptional findings reflect and parallel our in vivo and in vitro 
findings that there is a gradual, cell-intrinsic transition in HSCs throughout division.  
 
Next we manually inspected the differentially expressed gene lists. Sca1 (Ly6a) 
expression decreases with division, which correlates well with our surface expression 
data. We then examined the cell surface expression of other surface markers with 
significantly changed expression between d0 and d5. Two especially interesting 
candidates emerged. One is Alcam (CD166), a surface glycoprotein important for cell-
cell contacts that plays a role in HSC repopulation capacity 21. We found a progressive 
inverse change in surface expression of ALCAM with division (Fig 3.S2A, B). Another 
two significantly changed genes are CD41 (Itgab) and CD61 (Itgb3) (data not shown). 
CD41/CD61 forms a functional integrin complex. We find that CD41 shows a strong 
positive correlation with division (Fig 3.S2C, D), while CD61 has high cell surface 
expression throughout division (data not shown).  
 
Lnk deficiency retards the change in surface expression of HSC markers that 
occurs throughout division 
Recently there have also been reports showing that expression level of surface markers 
correlates with HSC function. Within the c-kit-gated population c-kit surface expression is 
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distributed across an approximate 10-fold range. Within that, high potency HSCs are 
found in the lower portion of that range, while cells in the higher range are only capable 
of intermediate term reconstitution of recipients 22-24. Given the strong negative 
correlation in HSC function that we have shown with each division, we asked whether 
the surface expression range of c-kit would be correlated with division status. Indeed, we 
find a strong positive correlation between c-kit expression and division in WT SLAM LSK 
(Fig 3.5A, left). In Lnk-/- SLAM LSK, this correlation is also present (Fig 3.5A, right), but 
notably d3 and d4 have a significantly lower relative c-kit expression, indicating more 
potent HSCs, than their WT counterparts (Fig 3.5B). These findings offer further 
evidence of the role of LNK deficiency in promoting the HSC identity, and also may point 
towards a mechanism.  
 
Based on this observation, we asked whether other surface markers correlated with 
division and whether the correlation was changed by Lnk deficiency. We first looked at 
well-known HSC markers Sca1 (Fig 3.5C, D), CD150 (Fig 3.5E, F), and CD48 (Fig 3.5G, 
H). Sca1 surface expressions showed a very strong negative correlation with division in 
WT SLAM LSK, consistent with a recent report correlating high Sca1 surface expression 
with HSC function 13. Interestingly, this progression is significantly tempered in Lnk-/- 
SLAM LSK (Fig 3.5D). CD150 and CD48 expression changes have not conclusively 
been linked to functional outcomes for HSCs, nevertheless there is a quantifiable 
change in surface expression with division (Fig 3.5F, H). In these populations, Lnk 
deficiency also tempers expression changes (Fig 3.5F, 5H). Taken together, these data 
show changes in cell surface receptors surface expression that correlates with division 
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status and HSC function. This suggests that Lnk could be involved in regulating stem 
cell identity through cell surface receptor stability in a transcription-independent way. 
 
In vivo division history marks HSCs independently of surface marker profiles 
Prospective HSC purification remains an elusive goal. One other potential application of 
this work is to identify a surface marker scheme with high specificity and sensitivity; that 
is, a marker scheme that identifies only the entire population of functional HSCs. SLAM 
LSK markers enrich HSCs to 1 out of 3 and only partially overlap with other marker 
schemes such as CD34-Flk2-LSK. Additionally, CD150- side-population also repopulate 
hosts 25, further underscoring the inadequacy of surface markers to accurately reflect the 
entire HSC pool.  
 
By FACS analysis, there is a clear population of d0 cells in CD150- (Fig 3.6A), and 
CD34+ (Fig 3.6B) subsets of CD48-LSK. Some CD34-Flk2- LSK are also CD150-, so we 
expected there to be repopulating activity in the CD150- CD48- LSK compartment. Since 
we have shown that in vivo division history strongly negatively correlates with HSC 
function, we wondered whether those HSCs would be found in the d0 subset. We 
therefore assessed the repopulation capacity of CD150+ or CD150- d0 cells from WT or 
Lnk-/- mice by transplant. Strikingly we found that both compartments were capable of 
long-term reconstitution (Fig 3.6C). Similarly, some SLAM LSK are CD34+. To test 
whether those cells were found in d0 subset, we performed a similar experiment on 
CD34+Flk2- LSK gated cells. Similarly, we found that CD34+ in d0 cells also 
reconstituted hosts (Fig 3.6D). We then also investigated the expression of a known 
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marker of intermediate-term HSCs, CD49b (Fig 3.6E). Consistently, CD49b+ cells in d0 
were able to repopulate recipients from both WT and Lnk mice (Fig 3.6F). For 
comparison, we also transplanted CD49b+ or CD49b- cells from d4 and neither was 
capable of repopulation (Fig 3.6F). Taken together these data strongly demonstrate that 
division status is a better determinant of HSC function than any single surface marker 
scheme. 
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3.4 Discussion 
 
Here we show that in vivo, HSCs exist in a continuum of repopulating and self-renewing 
capacity and that this continuum is organized by their in vivo division history. We devise 
and characterize a system by which to study the enhanced self-renewal capacity 
associated with Lnk deficiency in vivo and we molecularly probe the transcriptional and 
surface expression changes between division subsets in Lnk deficient HSCs. 
 
In this manuscript we provide several lines of evidence to demonstrate that in vivo 
division imparts cell-intrinsic changes to HSCs. In both WT and Lnk deficient mice there 
is a dilution of repopulating and self-renewal capacity as well. Using this model we also 
demonstrate that Lnk deficiency retards dilution of HSC function with division, retaining a 
frequency of at least 1/50 functional HSCs in d4. These are bona-fide stem cells, with 
self-renewal capacity as evidenced by robust reconstitution of secondary recipients.  
 
The decreasing reconstitution capacity of SLAM LSK with in vivo division correlates well 
with our in vitro findings that d0 cells exit quiescence later than cells in other subsets. 
Furthermore, we demonstrate that each in vivo division progressively changes cells, with 
each division shifting cells towards an earlier response to mitogenic stimuli. Even one in 
vivo division is sufficient to significantly reduce the lag in responsiveness to growth 
signals. It is intriguing to hypothesize that there may be an underlying functional 
advantage to activated but non-dividing HSCs. A parallel is seen in muscle stem cells, 
were activation of stem cells in one location induces a transient state of responsiveness 
to stimuli in muscle stem cells in a second, distant location 26, raising the intriguing 
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possibility that infrequent HSC division may be a mechanism to maintain sensitivity in 
HSCs. It would be interesting to further probe functional changes with each in vivo 
division. 
 
Finally, we see the same trend in genome wide transcriptional profiling of division 
subsets. The findings from our in vitro study are reflected in the profiling data, which 
shows that cells in later in vivo division subsets have a transcriptional program tuned for 
division. The data is validated by surface expression changes and agrees with published 
findings. Notably, d0 subsets overlap transcriptional profiles with a core set of genes 
enriched in functional HSCs, which was described from individual transcription profiles of 
cells that had been sequenced and correlated with functional output. This study also 
identified high expression of Sca1 and EPCR on LT-HSCs 13, and we also find 
correlation between these markers and division by gene and cell surface expression. 
Another noteworthy correlation is with a study that identified CDK6 as a driver of HSC 
proliferation and differentiation 10, blockade of which could protect HSCs from exhaustion 
due to proliferative stress 27. We find that CDK6 is significantly upregulated in d5+ cells. 
Our work adds an extra dimension to these studies, providing some insight into the order 
of transcriptional changes as cells lost self-renewal capacity.  
 
Future studies will aim to dissect the molecular underpinnings of how Lnk deficiency 
influences HSC self-renewal propensity in vivo. We have identified several potential 
future directions from the transcriptional data. First, changes in ALCAM or CD41 may be 
drivers of self-renewal propensity. Though we have not yet compared ALCAM and CD41 
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surface expression between Lnk-/- and WT mice, it is intriguing to speculate that one of 
these functional surface proteins may be altered by LNK deficiency and lead to a 
preference for self-renewal. Notably, in contrast to its embryonic role 28, CD41 surface 
expression enriches for progenitors in adult BM 29. The binding partner of CD41, CD61, 
forms another integrin complex, CD51 (Itgav), which is highly and uniformly expressed 
among division subsets at a gene expression level (data not shown). CD61/CD51 
surface expression is associated with long term repopulation capacity in HSCs while 
CD61/CD41 surface expression is associated with short term progenitors 30. Crucially, 
CD61/CD51 is activated by TPO signaling through which LT-HSC activity is preserved 
during in vitro culture 30. Integrins participate in orienting the cell division axis, and 
therefore influence cell fate decisions {Streuli:2009jo}. In addition, LNK deficiency has 
been shown to directly regulate integrin activity in endothelial cells 31, and specifically the 
CD41/CD61 integrin complex in platelets 32. Therefore, it would be interesting to 
determine whether LNK regulation of HSC integrins is an important mechanism in its role 
in regulating self-renewal. 
 
 A second potential driver is through the Retinoic Acid (RA) signaling pathway, activation 
of which has been reported to promote LT-HSC repopulating capacity 33 and be required 
for the maintenance of dormancy in HSCs 20. In d0 we see significant enrichment of 
retinoic acid response elements Rxra and Rxrb, but also Cyp26b1, the enzyme 
responsible for degradation of all-trans retinoic acid (ATRA). Conversely, in d5+ we see 
upregulation of ATRA synthesis, by enrichment of Aldh1a1 expression (the rate-limiting 
step enzyme), though ALDH1A1 has been shown to be nonessential in HSCs 34. Stat5, 
the transcriptional effector of Tpo/TpoR/Jak2 signaling in HSCs, is known to bind the 
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same sites as some retinoic acid elements and synergize with RA mediated transcription 
35. Ongoing work is aimed at probing the effect of Lnk deficiency on this signaling 
intersection.  
 
Additionally, our data show evidence of a potential role for Lnk deficiency to impact 
HSCs at a protein level. Our data convincingly shows the changes in surface expression 
with division of several HSC-associated proteins is decelerated by Lnk deficiency. It has 
previously been demonstrated that the level of c-kit surface expression is regulated by 
CBL, a ubiquitin ligase that targets proteins for degradation. Higher CBL activity was 
associated with lower c-kit surface expression and therefore higher HSC potency 23. 
Intriguingly, by mass spectrometry, we have found that LNK binds CBL (unpublished 
data), and therefore LNK may alter CBL activity and protein expression at the surface 
and intracellularly, thereby increasing the likelihood of self-renewing division. 
 
There are two key challenges going forward in this study. The first is that, though in vivo 
division history is traced by H2B-GFP dilution, neither the timing of division nor the 
relationship between division subsets can be directly inferred. It is certainly possible that 
some cells in d4 have initiated and undergone rapid division very close to the end of the 
4 week chase period, while other d4 cells have divided once every 4 weeks. Though our 
in vitro data would suggest that d4 cells behave relatively uniformly to division stimulus, 
it is clear by transplant that the d4 subset is a heterogeneous population. Given that self-
renewal often occurs as an asymmetric division during homeostasis 36 37, we expect that 
HSC function might be lost before surface marker profiles begin to change. Another 
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possibility is that the surface marker expression profile among cells in different division 
subsets of SLAM LSK is not constant, meaning that, for example, some cells in d4 did 
not originate from a d0 SLAM LSK but later acquired the SLAM LSK surface marker 
profile. While these questions could be explored with the help of another biomarker, 
such a second pulse-chase label that could be applied at variable intervals during the 
H2B-GFP pulse-chase, this would ultimately lead to the same population-based data. 
 
The second challenge is that there are significant limitations to studying HSCs by 
surface markers. Foremost is that many surface markers are not functional. Second, 
surface markers only enrich HSCs. By the most up to date surface marker scheme, only 
1 in 2 cells are bona-fide HSCs. Additionally, recent evidence shows that in steady state 
in vivo progenitors contribute extensively to maintaining hematopoiesis, and not the cells 
designated “LT-HSCs” 38. Finally, HSCs exist as a functionally heterogeneous population 
at the single cell level, as a mix of cells with propensities towards a particular lineage 9. 
All this calls into question the study of HSCs as a population and based on a phenotypic 
description and highlights the necessity to study HSCs at a single cell level. 
 
This approach will allow for several advantages over population-level profiling. First, 
rigorous quantification of HSCs within each division subset in WT and Lnk-/- mice by 
limiting dilution assay will determine the nature of the dilution in repopulation capacity 
that we observe – whether HSC quantity or quality change, or both. Together with 
single-cell transcriptional data, it will be possible to independently cluster and map how 
closely cells within each division subset are related to one another. Second this 
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approach will be able to determine whether Lnk-/- HSCs preserve a specific 
transcriptional program regardless of division history. Finally, this approach will be able 
to answer whether the impact of Lnk deficiency is at a transcriptional or post-
transcriptional level. At present, it is thought that transcription may be only one 
component of self-renewal determination. Since self-renewal is defined at the moment of 
division, which often involves the asymmetric inheritance of HSC function into only one 
daughter cell 36 37, it is not unreasonable for an HSC-niche interaction or asymmetric 
protein distribution to potentially be the actual driver of this asymmetrical inheritance of 
function. Indeed, multiple HSC-niche interactions such as with E-SELECTIN 39 or CXCL4 
and niche megakaryocytes 40 41 42, drivers of asymmetric protein distributions such as 
LIS1 43, and even level of protein synthesis 44 have been reported to impact HSC 
function. Therefore, future studies should also include single cell level protein profiling 
such as by the recently developed mass cytometry 45, particularly in paired cells after 
division. 
 
Taken together, we show LNK deficiency shifts the in vivo HSC continuum towards the 
stem cell side, and establish several leads that may elucidate the mechanisms behind 
enhanced self-renewal in Lnk -/- HSCs. 
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3.5 Materials and Methods 
Mice 
Rosa M2R- tTA; collagen H2B-GFP (H2B-GFP) mice were kindly provided by Dr. Hanno 
Hock (Massachusetts General Hospital and Harvard University, Boston, MA) 2. Lnk-/- 
mice by Dr. Tony Pawson (Samuel Lunenfeld Research Institute, Canada). H2B-GFP 
mice were bred with Lnk-/- mice to create M2R; H2B-GFP; Lnk-/- animals. All mice were 
on C57/B6J background (CD45.2) and both male and female mice were used in 
experiments. Transplant competitor cells were from SJL (CD45.1) mice and transplant 
recipients were progeny of SJL x C57/B6J (F1). To induce H2B-GFP expression, 6-8 
week old mice were given water supplemented with 2mg/mL Doxycycline (Sigma 
D9891) and 5% sucrose three times a week for a period of six weeks (“label” period). At 
the end of the label period, mice were returned to normal drinking water (“chase” period). 
After four or six weeks, mice were sacrificed and bone marrow was harvested from 
tibias, femurs and ilia. Bone marrow was flushed using 0.5% bovine serum albumin 
(BSA) (Fisher, BP1600-100) in PBS. Cells were passed through a 30µm nylon filter to 
make a single cell suspension. 
 
Genotyping 
Mice were genotyped by PCR of genomic DNA from tail snips of weanling mice. Tails 
were digested at 55°C overnight in buffer containing 100mM Tris pH 8.0, 5mM EDTA pH 
8.0, 0.2% SDS and 200mM NaCl. DNA was precipitated in propanol and washed in 70% 
EtOH and then resuspended in water. Mice were genotyped for Lnk (wild-type: 5’-
gtccgactctctggctatgtggta-3’, neo insertion: 5’- cgcatcgccttctatcgcct-3’, common: 5’- 
	94	
	
gaagaggagtccatgtcatagtcc-3’), M2R-tTA (5’-aaagtcgctctgagttgttat-3', 5’-
gcgaagagtttgtcctcaacc-3', 5’-ggagcgggagaaatggatatg-3'), and H2B-GFP (5’-
gcacagcattgcggacatgc-3', 5’-ccctccatgtgtaccaagg-3', 5’-gcagaagcgcggccgtctgg-3'). 
 
Sorting 
Sorts for transplant and RNAseq were performed on one of two different instruments. 
First, HSPCs were pre-enriched using a lineage depletion kit (Miltenyi, 130-090-858) and 
magnetic separation column (Miltenyi, 130-042-401) following manufacturer’s 
instructions. Briefly, bone marrow from individual mice was resuspended in 150µL of 
2mM EDTA 0.5% BSA PBS pH 7.2 (depletion buffer) and 40µL of Lineage antibody 
cocktail. Cells were incubated at 4°C for 15 minutes, then washed in 10 mL of the 
depletion buffer. Cells were resuspended in 250µL depletion buffer and 70µL Biotin 
conjugated microbeads, and incubated and washed again. Cells were resuspended in 1 
mL depletion buffer and passed through a 30µm nylon mesh into the separation column. 
Columns were washed with 3x3mL depletion buffer. LT-HSCs (SLAM LSK) were stained 
with anti- c-kit, -Sca-1, -CD48, and -CD150 antibodies. GFP divisions were resolved by 
individual peaks, and verified by Geo Mean (two-fold dilution after each division; 
GeoMeandX= GeoMeand0/2X). For the paired WT and Lnk -/-transplant, cells were double 
sorted on a BD Aria sorter with a 70µm nozzle. On the first sort, LSK were enriched 
using the “yield” setting, then highly purified LT-HSCs in division 0, 2, 4, or 5+ were 
sorted using a “single cell” drop envelope into 1.7mL tubes containing StemSpan SFEM 
(STEMCELL Technologies, 09600) with 2% fetal bovine serum (FBS) (SAFC 
Biosciences, 12103C-500mL). For RNAseq analysis, division subsets were sorted only 
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once on a BD Aria sorter using the “single cell” drop envelope directly into 1.7mL tubes 
containing Trizol LS (Thermo Fisher 10296028). For all other transplants and for in vitro 
division sorts, LT-HSCs were double sorted using the MoFlo Astrios EQ with on the “low 
pressure” setting. First LSK were enriched using the “enrich” setting, then LT-HSCs in 
different division subsets were sorted into individual wells of a 96 well plate containing 
100µL of 2% FBS SFEM. Competitor cells were added directly to each well in 50µL of 
PBS and then transplanted as described below.  
 
Bone Marrow Transplant 
Sorted LT-HSCs separated by division status from donor mice were mixed with 350,000 
freshly isolated competitor (B6.SJL) cells or 400,000 Sca1-depleted competitor cells and 
injected retro-orbitally into lethally irradiated (10Gy, split dose, Orthovoltage Precision X-
Ray) F1 recipient mice in 100-150µL of PBS per recipient. At 4, 8, 12 and 16 weeks post 
transplantation, peripheral blood of recipients was analyzed for donor reconstitution in 
myeloid, T-, and B- lineages by flow cytometry. At 16 weeks post transplant, recipients 
were sacrificed and donor reconstitution in various HPSC compartments was analyzed 
using flow cytometry. BM cells from primary transplants were harvested and 2 million 
cells were injected into each secondary recipient. 
 
Flow Cytometry 
For peripheral blood analysis, 50µL of peripheral blood was collected by retro-orbital 
bleed in heparinized microcapillary tubes (Drummond 1-000-7500-HC/5). Red blood 
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cells were lysed with ACK lysis buffer (0.8% ammonium Chloride, 10 µM EDTA, pH 7.5 
with sodium bicarbonate). Cells were stained for donor reconstitution (CD45.1, CD45.2) 
in myeloid (Gr-1, Mac1) or lymphoid (CD19, CD3) lineages. All peripheral blood data 
was acquired using BD Canto flow cytometer and FACS DiVa software. At least 20k live 
events were recorded for each sample. For donor reconstitution in bone marrow of 
transplant recipients, cells were stained with fluorophore-conjugated anti-CD45.1, 
Lineage (biotin-Ter-119, -Mac-1, -Gr-1, -CD4, -CD8α, -CD5, -CD19 and -B220), -c-kit, -
Sca1, -CD150, -CD48, followed by staining with streptavidin-PE-TexasRed. For 
evaluation of additional surface markers, LT-HSCs were pre-enriched and stained with 
SLAM LSK or CD34 and Flk2 LSK panels as described, and additionally with anti-CD41, 
or –ALCAM antibodies. Data for bone marrow analysis was collected on the BD LSR 
Fortessa flow cytometer and FACS DiVa software. All flow cytometry data was analyzed 
using FlowJo v8.7 for MAC. All antibodies used for flow cytometry are detailed in 
supplemental table 2. 
 
In vitro division assay 
For time to first division in vitro, one single cell was sorted into each well of a round 
bottom 96 well plate (Costar 3799) containing 100µL of 10% FBS SFEM supplemented 
with 1% penicillin/streptomycin (Life Technologies, 15140-122), 1% L-glutamine (Life 
Technologies, 25030-081), 100µM β-mercaptoethanol (Sigma, M7522), 10 ng/mL 
murine Tpo (Peprotech Inc, 315-14), and 50 ng/mL murine SCF (Peprotech Inc, 250-03). 
Media was filtered through a 0.22µm membrane (Millipore SLGV013SL) prior to 
aliquotting into plates. Cells were incubated at 37°C with 5% CO2. Starting from 14-16 
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hours after sorting, each well was inspected individually using an inverted light 
microscope every two hours until the end of the 72h observation period. Wells in which 
zero or more than one cells was initially observed were excluded from analysis. The time 
to first division was counted as the first hour during which two separate cells were visible 
in a well. The time to second division was counted as the first hour during which four 
separate cells were visible in a well. 
 
RNA seq 
Two replicates of RNA libraries were prepared from 20,000-40,000 single sorted cells 
from five mice each. 500µL of Qiazol (Qiagen 79306) was added to each sample. 
Samples were spun for 15 minutes at 4°C 12,000xg and the liquid phase was transferred 
to a new tube and mixed with 1.5x volume 200 proof ethanol. RNA was isolated using 
the miRNeasy (Qiagen 217004) kit according to manufacturer’s instructions, with the 
following modifications: columns were replaced by ones from the MinElute cleanup kit 
(Qiagen 28204), and flow through after column loading was collected and loaded a 
second time to increase yield. DNA was digested using DNase I (Qiagen 79254). Beijing 
Genomics Institute (BGI) at CHOP performed sequencing library construction and 
sequencing. Briefly, BGI prepared amplified cDNA using SPIA amplification (NuGEN) 
and created a paired-end sequencing library using the Ovation Ultralow Library System 
(NuGEN). Samples were sequenced on an Illumina HiSeq 2500 Sequencing System 
(Illumina) using a PE100 flow cell to a depth of 80-100 million reads per sample. 
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RNAseq samples were analyzed for differential expression as follows. Reads were 
aligned using STAR 2.4.2a with default parameters 46. STAR genome indices were 
generated using the UCSC mm9 genomic sequence, and genes annotated using the 
UCSC mm9 RefSeq GTF files (RefFlat version). Reads were tabulated using HTSeq-
0.6.1p1 47. Using R.3.2.4 and DESeq2 v3.2 48, differentially expressed genes were called 
with adjusted p-values less that 0.1.  Graphic outputs used regularized logarithm 
adjusted data. Gene Set Enrichment Analysis (GSEA) 49 50 was performed using 
MSigDB v6.0 and enrichments were significant called at FDR≤0.2 and/ or p≤0.05. 
 
Statistical analysis 
All statistical comparisons across samples were calculated by two tailed-student’s t-test.
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3.6 Figures	
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3.7 Figure Legends	
Figure 3.1: The HSC pool is a continuum of HSC subtypes with distinct cell cycle kinetics 
and self-renewal/ differentiation properties. (A) Peripheral blood analysis 16 weeks after 
transplant of 200 WT SLAM LSK (gray) or 100 Lnk-/- SLAM LSK (red) into lethally irradiated 
recipients together with 400k competitor cells is shown. For all transplant data, each symbol 
represents one animal, black bars represent the mean of each group. Horizontal lines indicate 
direct comparison. ‡ indicates comparison to WT d0 and ◊◊◊ indicates comparison to Lnk-/- d0. ‡ 
or ◊ signify p<0.05, ‡‡ or ◊◊ signify p<0.01, and ‡‡‡ or ◊◊◊ signify p<0.001. (B) Analysis of 
peripheral blood 16 weeks after secondary transplant of 1 million total BM from primary 
recipients is shown. (C) The donor derived SLAM LSK frequency in bone marrow of primary 
recipients after 16 weeks is shown. Donor frequency was calculated as follows: 
(donor%)*(SLAM LSK%). (D) Lineage composition of donor derived cells is shown in Myeloid 
(M), B cells (B) and T cells (T) in the peripheral blood of primary recipients 16 weeks after 
transplant. Mice with donor reconstitution below 1% in all lineages were excluded from this 
analysis. All comparisons are not significant. (E) Lineage composition of donor-derived cells is 
shown in M, B, and T cells in the peripheral blood of secondary recipients 16 weeks after 
transplant. 
 
Figure 3.2: Cell intrinsic properties conferred by in vivo division are maintained in vitro. 
(A) The division status of SLAM LSK in Lnk-/- mice after six weeks of chase was assessed by 
flow cytometry. The distribution of cells by division is shown, n=3. (A, D, E) Bars indicate 
means, and vertical lines indicate SE. (B) 50 SLAM LSK in division subsets d0, d2, and d4 were 
transplanted into lethally irradiated recipients together with 350,000 total bone marrow 
competitor cells. Shown is donor reconstitution of peripheral blood 16 weeks after transplant. (C) 
Individual cells were sorted into wells of round bottom 96 well plates and visualized every two 
hours for division. Time of division was noted as the first hour during which two individual cells 
were visible in a well. Median time to first division is charted by dotted lines. Each symbol 
represents the average number of cells per well. d0, d1, d2, and d4 are indicated by a diamond, 
cross, square and circle, respectively. The number wells counted is n=93, n=86, n=90, n=88 for 
d0, d1, d2, and d4 respectively. (D) The mean time to first division is quantified, and the 
numerical value is written in each bar. (E) The number of hours between the first and second in 
vitro division is quantified. (F) The average number of cells per well throughout the 72h 
observation period is shown. 
 
Figure 3.3: Lnk HSCs have slower division kinetics in vitro. (A) Individual cells in division 0, 
2 or 4 from WT and Lnk-/- mice were sorted into round bottom 96 well plates and visualized for 
division every two hours. Cells were tracked for 72h. Time to first division in hours is shown, 
plotted as the percent of wells in which the single cell has divided at least once. Time of division 
was noted as the first hour during which two individual cells were visible in a well. Median time 
to first division is charted by dotted lines. Each symbol represents the average number of cells per 
well. Only seven time points are displayed for clarity. n=3 for Lnk-/- and n=1 for WT, results 
from one paired experiment are shown. d0, d2 and d4 cells are indicated by diamonds, triangles 
and circles, respectively. The number wells counted for WT cells is n=82, n=86, n=89 for d0, d2, 
and d4 respectively. The number wells counted for Lnk-/- cells is n=84, n=83, n=81 for d0, d2, 
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and d4 respectively. (B) The time in hours to first division for d0, d2, and d4 from WT and Lnk-/- 
mice cells is shown. (B, C) Bars represent the mean and vertical lines represent SE throughout all 
graphs. The numerical value of the mean is displayed inside each bar. The result of statistical 
comparison of means by two-tailed student’s t-test is indicated above the bars, ns indicates not 
significant p value, * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001. (C) 
displays the mean number of hours between the 1st and 2nd divisions in vitro for d0 and d4 cells 
from WT and Lnk-/- mice. (D) Cell number over the 72h observation period is plotted for d0, d2, 
and d4 cells from WT and Lnk-/- mice. 
 
Figure 3.4: Genome wide gene expression correlates with HSC division continuum. (A) 
shows unsupervised clustering using Spearman correlation among biological replicates and 
samples from d0 (purple), d2 (green), d4 (orange), and d5+ (teal) SLAM LSK subsets. (B) 
Differential gene expression was calculated using DESEq2 and the number of significantly 
changed genes from each comparison is shown in the table. (C) K-means clustering analysis 
shows four clusters of differentially expressed genes. Each gene is scaled relative to expression 
across subsets by Z-score. Clusters are indicated by vertical lines. Color indicates level of gene 
expression; low expression is colored in blue, while high expression is colored in red. Division 
subsets are indicated at the bottom of the heatmap, biological replicates are indicated by 
horizontal lines. (D) shows top 15 Gene Ontology terms for each Cluster. GO terms are ranked by 
fold enrichment. (E, F) GSEA enrichment for each pairwise comparison between division subsets 
is shown for Hallmark Genesets (h.all.v6.0).  
 
Figure 3.5: HSC in vivo division history best represents HSCs. (A) CD150 intensity is plotted 
against GFP intensity in CD48-LSK cells from Lnk-/- mice. Clear CD150 positive and negative 
fractions are visible in division zero. n= 16, one representative image is shown. (B) CD34 
intensity is plotted in CD48- LSK. n=5, one representative image is shown. The gray dotted line 
represents the cutoff between positive and negative set by a fluorescence minus one control. 
Dotted fuchsia lines indicate sort gates. (C, D, F) CD48- LSK were gated on division 0 and 
additionally selected by CD150, CD34 or CD49b as indicated in each panel. 20 double-sorted 
cells were transplanted into lethally irradiated recipients together with 400,000 Sca-1 depleted 
competitor cells. Donor reconstitution in peripheral blood is shown 16 weeks after transplant. (C) 
shows donor reconstitution for CD150 positive or negative CD48- LSK from WT or Lnk-/- 
donors. (D) shows donor reconstitution for CD34 positive or negative CD48- LSK from WT 
donors. (E) CD49b is plotted against GFP in SLAM LSK cells. n=6, one representative image is 
shown. (F) shows donor reconstitution for CD49b positive or negative SLAM LSK from WT or 
Lnk-/- donors. In addition, CD49b positive or negative SLAM LSK cells in division 4 were 
transplanted from Lnk-/- donors. 
 
Figure 3.6: Lnk deficiency sustains stem cell markers throughout division. (A, C, E, G) 
Surface marker intensity was plotted against GFP in SLAM LSK cells from bone marrow of WT 
and Lnk-/- mice. (B, D, F, H) The geometric mean was calculated for each division subset and 
normalized relative to the intensity at division 0. Bars represent means and vertical lines represent 
SE. Statistical comparisons between WT and Lnk-/- cells with p≤0.05 are indicated above the 
bars. * indicates p<0.05, and ** indicates p<0.01. Comparisons with d0 within each genotype is 
	114	
	
indicated by a double cross (‡) or diamond (◊) for WT or Lnk-/-, respectively. ◊ or ‡ indicate 
p<0.05, ◊◊ or ‡‡ indicate p<0.01, and ◊◊◊ or ‡‡‡ indicate p<0.001. Four recognized stem and 
progenitor -associated cell surface markers were analyzed. (A) The intensity of c-kit is plotted 
and (B) quantified, n= 9 for Lnk-/- and n=5 for WT. (C) The intensity of Sca-1 is plotted and (D) 
quantified, n= 7 for Lnk-/- and n= 5 for WT. (E) The intensity of CD150 is plotted and (F) 
quantified, n=16 for Lnk-/-, n=5 for WT. (G) The intensity of CD48 is plotted and (H) quantified, 
n=8 for Lnk-/- and n=5 for WT. 
 
 
Figure 3.S1: H2B-GFP captures the heterogeneous state of division of SLAM LSK cells. (A) 
H2B-GFP expression is induced by doxycycline administered in drinking water during “pulse” 
period for 6 weeks. Signal is diluted during “chase” period for four weeks. Signal retention is 
then examined in bone marrow.  (B) Histogram plots demonstrating that label retention by GFP 
intensity is enriched in stem cell populations. Pictured are LK, LSK and SLAM LSK populations 
of WT and Lnk-/- mice. (C) Label retention is quantified in SLAM LSK between WT and Lnk-/- 
mice (n=6, and n=17, respectively). *= p<0.05, **=p<0.01. 
 
Figure 3.S2: Division impacts several cell surface markers. (A) shows a representative plot of 
ALCAM surface expression across division subsets in SLAM LSK of Lnk-/- mice. (B) Mean of 
ALCAM intensity is quantified across division subsets relative to division 0. n=4 mice. (C) 
shows a representative plot of CD41 surface expression across division subsets in SLAM LSK of 
Lnk-/- mice. n=4. (D) Mean CD41 intensity is quantified across division subsets relative to 
division 0. (E) shows a representative plot of CD61 surface expression across division subsets in 
SLAM LSK of Lnk-/- mice. n=4, one plot is shown. Bars indicate mean. Statistical comparisons 
between surface marker expression relative to d0 are indicated above bars. ◊ indicates p<0.05, ◊◊ 
indicates p<0.01, and ◊◊◊ indicates p<0.001. Individual pair-wise comparisons are indicated by a 
horizontal bar, and p<0.05 is indicated by *. 
	
Supplemental Table 1: High quality sequencing reads are obtained from input. Table shows 
total reads, uniquely and multiple mapped reads, and mapped reads as percentage of total reads 
for each replicate and sample submitted for RNA sequencing. 
 
Supplementary Table 2: Antibody clones and suppliers 
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CHAPTER 4 Discussion 
 
Together this body of work investigates the impact of Lnk deficiency in HSCs. In chapter 
2, we show that in context of FA bone marrow failure, Lnk deficiency rescues the 
functional HSPC defects associated with Fancd2 deficiency and crucially, mitigates 
genome instability. The second is an investigation of the mechanism underlying 
increased HSC self-renewal in Lnk-/- HSCs. The findings presented here shed light on 
the mechanism of Lnk function and impact on HSC biology and offer a potential 
opportunity to manipulate HSCs through transient incapacitation of LNK. 
 
4.1 The impact of Lnk deficiency on FA 
	
4.1.1 Summary of research findings and conclusions 
	
There is much effort devoted to elucidating the roles of known FA proteins and 
identifying new members. As more information becomes available, it becomes 
increasingly clear that FA family members participate in a diverse set of roles. FANCC 
has been shown to mediate an extra-nuclear role in detoxifying reactive oxygen species 
1. Equally importantly, FANCC and FANCD2 have also been reported to promote 
autophagy through which they exert regulation over protein quality control and this role 
independently contributes to cell viability 2. FANCD2 is also important in resolving 
microbridges during anaphase and preventing microsattelite nuclei 3 4 5. The impact of 
these emerging roles for FA proteins is less clear, but the roles are as varied as they are 
numerous. 
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Though BMF in FA is currently treatable by BMT, a more permanent approach towards 
FA phenotype correction, of course, is through gene editing to directly correct the 
causative mutations. Recent advances in genome editing techniques, most notably via 
the bacterial-derived CRISPR-Cas9 system, make genome editing a possibility in FA 
cells. However before such an approach can be a viable therapeutic modality, several 
challenges must be overcome. First, the ability to effect gene correction by CRISPR-
Cas9 necessarily proceeds through a homologous recombination, the very mechanism 
that is defective in many subsets of FA. This creates an obvious roadblock in the 
efficient and safe integration of gene correcting sequences into the genome. Second, 
cells that can be removed from the body, modified, and then returned- such as HSCs- 
may be effectively targeted by a gene editing mechanism. Unfortunately, most cells 
would be not be targetable through this approach, leaving them still vulnerable to the 
hallmark FA-associated susceptibility to cancer. Epithelial head and neck, cancers, for 
example, have been documented in 5% of FA patients in the FA database 6 and the 
probability of solid tumor development is 76% in patients without leukemia or aplastic 
anemia 6. Together these drawbacks of direct gene correction therapy demonstrate the 
importance of independent genome instability –reducing interventions. 
 
Two main studies demonstrate improvement in FA manifestations by non-curative 
means. The first study demonstrates that apoptosis in FA cells is p53 dependent 7. p53 
is basally activated in FA cells from patients as well as in BM cells from Fancg deficient 
mice. p53 mediates a cellular response that involves G1/G0 arrest in FA cells and 
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ultimately activates cell death through apoptosis. Predictably, knockdown of p53 
improves cell survival, which is also correlated with a rescue in LSK frequency in 
FancD2 deficient mice. What is especially noteworthy is that human cells with 
knockdown of p53 and FancD2 show improved reconstitution of recipients over 
reconstitution by FancD2 knockdown cells. It is important to note, however, that the 
reconstitution decreases over time, indicating cell exhaustion. Though p53 deletion as a 
treatment for FA is of course out of the question due to the genomic instability and 
cancer predisposition conferred by p53 inactivation, this study demonstrates for the first 
time that overcoming the consequences of accumulating DNA damage alone has 
significant impact on FA HSC function and lays the groundwork for the feasibility of 
rescuing HSPCs function in the context of FA without bone marrow transplantation or 
direct gene correction. 
 
The second study addresses another signaling arm that is over-activated in FA cells: 
TGFβ. Here, the findings also demonstrate that overcoming the cellular consequences of 
FA deficiency is sufficient to improve HSC function 8. Small molecule inhibition or genetic 
deletion of key TGFβ components results in suppression of bone marrow failure after 
forced in vivo HSC proliferation and a rescue in colony forming capacity. Importantly, the 
amount of DNA damage after forced in vivo proliferation is decreased after TGFβ 
blockade, as evidenced by γH2AX accrual. Additionally, suppression of TGFβ shifts DNA 
repair towards HR utilization by restoring transcription of HR component genes, thereby 
increasing the odds of error-free DNA repair in FANCD2 deficient cells and improving 
genome stability.  
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Our findings parallel the conclusions that non-curative interventions can dramatically 
improve FA HSC function. In the context of FANCD2 deficiency, we demonstrate robust 
restoration of hematopoietic stem cell function in a rigorous serial transplantation assay 
by deletion of Lnk. Both HSC numbers and transplantability are restored to WT levels, 
simultaneously highlighting the importance of replication-associated stress in BMF and 
the impact of non-curative treatments on ameliorating the manifestations of FA. 
Crucially, in context of chronic proliferation induced by pI:pC we also demonstrate LNK 
deficiency rescues FA HSC reconstitution potential. Importantly, LNK deficiency reduces 
genome instability, and this is through augmenting stalled replication fork stability – a 
direct rescue of a FANCD2 function. In combination with another approach capable of 
either directly restoring crosslink repair or detoxifying damaging intermediates, Lnk 
deficiency highlights potential targets of therapeutic interventions in FA. 
 
4.1.2 Future Perspectives 
	
The role of LNK in human FA cells remains undertermined. This question deserves 
immediate attention. In humans, inactivating mutations in LNK protein are associated 
with JAK2-dependent neoplasms 9 or JAK2-independent erythrocytosis 10,11, indicating a 
similar function in suppression of cell proliferation in humans as in mice. Additionally, 
human HSPCs modified to suppress LNK expression show increased erythroid cell 
production 12, demonstrating that LNK does play a role in regulating human HSPCs. The 
role of LNK deficiency in the expansion and self-renewal of human HSCs is ongoing in 
	124	
	
the lab, as well as a parallel study on the impact of Lnk deficiency on HSC function and 
genome stability of human FA HSCs. 
 
Given the unexpected impact of LNK deficiency on replication fork stability in FancD2-/- 
cells, and by extension of cytokine signaling, it is easy to imagine that cytokine signaling 
might impact other functions of FA proteins. Our data conclusively rules out an impact on 
crosslink repair, but the impact of LNK deficiency on redox status and autophagy remain 
unexplored. In genome-wide profiling of LT-HSCs, we have previously shown an 
alteration in metabolic gene pathways in Lnk-/- HSCs, including enrichment in 
antioxidant genes 13. To that end, the role of Lnk deficiency in context of Fancg-/- or 
Fancc-/- will yield a definitive answer. Independent activity on redox homeostasis could 
be another way by which LNK deficiency prevents HSPC attrition, and was not explored 
in this work. If this is the case, however, then suppression of LNK would be a useful way 
to decrease DNA damage in FA cells. 
 
Cytokine signaling may play a role in genome-protection more broadly than only 
between LNK and FA. This role would not be unprecedented. TPO treatment increases 
radioprotection in IR-treated BM cells while LNK inhibits it 14 15. Given the role of cytokine 
signaling in protecting stalled replication forks it would be interesting to speculate 
whether Lnk deficiency could mitigate genome instability in context of deficiency of other 
fork-associated components, particularly BRCA2. BRCA2 mutated cells show high levels 
of genome instability, decrease in which decreases the risk for development of cancer 16 
17 18.  
	125	
	
 
In this regard, it would be especially important to investigate whether LNK deficiency can 
impact genome instability in extra-hematopoietic tissues. In BM, Lnk is expressed in 
several progenitor populations 19 but Lnk is also expressed in other progenitor 
populations, which include the brain and adipocyte progenitors 20 21. In brain, LNK 
deficiency is associated with improved proliferation of brain neural precursor cells after 
injury 20.  
Together such findings would add to the case for developing a way to suppress LNK in 
vivo as a therapeutic intervention. 
 
4.2 Cell autonomous changes throughout in vivo division and role of LNK in 
regulating self-renewal 
	
4.2.1 Summary of research findings and conclusions 
	
Self-renewal of HSCs remains an open topic in stem cell biology both for its enigmatic 
mechanism and for its potential therapeutic applications. Though several key players 
have been discovered, a thorough understanding of how self-renewal in HSCs occurs is 
still missing. Deletion of key self-renewal components often leads to extreme 
consequences for HSCs. As mentioned in the introduction, deletion of TPOR, for 
example, leads to rapid depletion of HSCs, and impaired reconstitution potential. At the 
other extreme, some deletions preserve self-renewal at the cost of differentiation, such 
as is the case for DNMT3 22,23. Others deletions or gains of function such as JAK2V617F 
enhance self-renewal and initiate malignant transformation. In this context, LNK 
	126	
	
deficiency offers a unique perspective into self-renewal because it simultaneously 
increases self-renewal capacity in HSCs without impinging on their capacity to 
differentiate and therefore provides an insight into studying self-renewal in a way that 
results in enhanced HSC function without impairment.  
 
HSCs are different from progenitors transcriptionally. Several studies have reported 
enrichment in mitogenic and proliferative signaling pathways in progenitors, setting 
HSCs apart by their quiescence 24 25 26. More recently, single cell profiling has more 
finely dissected these findings. One study sequenced single cells from populations 
enriched for stem cells 27. Their surface expression profiles during sorting were indexed 
and later compared against the transplantability of cells with identical surface profiles. 
This enabled an extrapolation of correlation between gene expression profile and 
functional output at a single cell level. Independent clustering revealed a common gene 
set associated with HSC function. Interestingly, these cells showed higher than average 
Sca1, and CD150 expression and lower than average CD48 expression, which 
correlates well with our d0 expression profile.  
 
Another profiling study, in which single HSCs were profiled based on label retention and 
surface markers against non-label retaining cells, also makes similar conclusions. This 
study demonstrates that dormant HSCs and activated HSCs exist in a continuum of 
states, aligned along a biosynthetic axis 28. Dormant HSCs are identified as label 
retaining and SLAM LSK, while active HSCs are non-label retaining in SLAM LSK, which 
is essentially like our profiling of d0 vs d5+ SLAM LSK. Indeed our findings are in 
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extensive agreement with this study. Interestingly, the study finds that all-trans retinoic 
acid maintains dormancy in HSCs. Changing trends in retinoic acid metabolism are also 
reflected in our gene expression profiling and represents an intriguing target for 
manipulation of self-renewal by LNK deficiency. Our study builds on this information by 
even more finely dissecting transcriptional profiles by each in vivo division and begins to 
investigate the relationship between cells after successive divisions. 
 
4.2.2 Future Perspectives 
	
Transcriptional profiling alone falls short of describing self-renewal completely. We have 
previously transcriptionally profiled the bulk SLAM LSK population and the resulting 
information was disappointingly scant: transcriptionally, Lnk-/- SLAM LSK are very 
similar to their WT counterparts. As is reflected in our data, fold change in expression of 
differentially expressed genes from cells across division subsets, where function vastly 
varies, actually vary only by a small amount. Interestingly, transcriptional profiles are 
also relatively stable through aging 29,30. This is true for LNK deficient HSCs as well 13. 
Whether the transcriptional changes we see are drivers or consequences of a cell fate 
decision is not distinguishable. The question arises, then, to what extent regulation of 
HSC self-renewal is post-transcriptional. 
 
There is mounting evidence that at least in part, self-renewal determination might be 
made at the post-transcriptional level. Self-renewing divisions are associated with 
asymmetrical inheritance of fate by asymmetrical inheritance of proteins in daughter 
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cells 31 32 33 34. We have previously shown that LNK binds a deubiquitinating complex, 
BRISC 35. JAK2 is marked by K63-linked ubiquitin after TPO stimulation, which serves 
as a mark for signaling activation. BRISC disassembles K63-linked ubiquitin chains, 
which attenuates JAK2 signal transduction. The cellular distribution of JAK2 at division 
has not been explored, but it is certainly possible that loss of Lnk could affect the 
distribution of Jak2 during cell division. 
 
Another, still emerging, self-renewal driver might be metabolic. The substrate for 
palmitoylation and the membrane anchors that establish polarity are metabolic 
intermediates. The availability of these intermediates can determine function. 
Cholesterol, for example, accumulates into local densities known as lipid rafts. These 
areas of membrane are stiffer than regular phospholipids in the membrane. Lipid rafts 
serve as organizing centers for signal transduction, and lipid rafts promote TPOR and c-
kit clustering, sensitizing cells to signal transduction 36 37. Furthermore, decreasing 
cholesterol level in HSCs suppresses their ability to proliferate and mobilize 38,39. 
Additionally, lipid composition has been shown to participate in orienting the cell division 
axis, which provides fate cues 40. Moreover, In our bulk SLAM LSK gene profiling, 
metabolic processes related to glycolysis, cholesterol synthesis and redox status 
dominated the enrichment categories in Lnk deficient HSCs 13.  
 
Finally, microenvironment may contribute to self-renewal choices. Several studies show 
the influence of niche interactions in cell fate decision, with daughter cells poised for 
differentiation dividing away from the niche 32. In this sense, cell surface proteins such as 
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integrins may help to determine whether a cell will be capable of receiving a self-renewal 
signal to begin with. If Lnk deficiency stabilizes cell surface expression of HSC markers, 
perhaps LNK deficiency improves the ability of HSCs to receive those self-renewal 
signals.  
 
Relatedly, another open question in Lnk-/- HSC biology is the localization of the 
expanded HSC compartment. It remains unknown whether Lnk-/- HSCs crowd the same 
number of niches or whether they simply create new ones. It would be interesting to 
determine whether Lnk -/- HSCs have enhanced self-renewal due to co-opting niches. 
 
4.3 Lnk deficiency as a mode of therapeutic intervention in HSCs 
Taken together, increased genome stability and enhanced self-renewal and repop 
ulation advantages make Lnk deficiency an attractive target for improving efficiency of 
gene therapy or transplant. Currently, two main challenges limit gene therapy: low 
engraftment after transplant and low editing efficiency 41 42. Given our findings, LNK 
deficiency may help address both issues.  
 
A second important application for LNK -/- HSCs is to improve engraftment and 
reconstitution during transplant. Myeloablative conditioning is a hard on recipients, 
especially in context of genome instability as in FA, where clearing the bone marrow 
space needs to be balanced against producing excess damage in other tissues. With the 
advantage LNK deficiency provides, transplants in which LNK is temporarily inhibited 
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might be able to produce a more robust reconstitution in recipients, and might reduce the 
need for severe conditioning. Of course, how LNK deficiency impacts human HSCs 
remains to be seen. 
 
Additionally, LNK is not considered a classically “druggable” target in itself since it lacks 
kinase activity. Therefore this highlights the need for further unraveling the mechanism 
of HSC fitness and expansion in LNK deficiency in order to discover such a target, or to 
look towards alternative strategies that might temporarily target LNK protein expression, 
such as inducible shRNAs or modified antisense oligos.  
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